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Onwards
Laura Hinz (Meds 2011)

hen fa ced with the wo rd " techno logy," images of robots,
supercomputers, and rn a sive e lectri ca l circuit spring to
mind . However, the concept of techno logy ste ms fro m
G reek th inkers, long before the introducti on of any of tho e devices . 1
Techno logy encompasses mo re than gadgets and gizmos, it invo lves
any nove l way of thinking, creating, or orga nizing that a ims to solve
a pro bl em. Thus Hea lth Techno logy was an ideal theme fo r an issue
of the U WO MJ , whose mandate has always been to in pire and
ce lebrate new, innovati ve approac hes to medi c ine.

W

In thi iss ue Dha liwa l and Ba llanty ne describe a tec hnique that
use the bodies own ce ll s to heal art icul ar cartil age injuries. Thi s
arti c le illustrates the perfect union between health and techno logy by
suggestin g the idea that if manipulated correctl y, the body itse lf can
be a so urce of hea ling. However, the technophiles will find the more
common concepti on of techno logy in an e loquent arti c le by
MacPherson and Rav ichand iran, describing adva nces in the fi e ld of
microfluidi cs eng ineerin g.
I approached thi s issue with a certa in degree of trepidati on, as
c ircuits and computer rema in reso lute ly beyond my grasp. Th ose
w ith s imilar limitati ons will find hope in Gotthe il and Kudl ow 's
arti cle, whi ch describes an adaptation of a commo n tec hno logy
(namely text messaging) to serv ice a hea lth ni che. Not onl y is thi s a
reso urce-e ffi c ient approach to techno logy, but it puts techno logica l
deve lopment within the gras p of eac h indi vidual. You do not need to
be an eng ineer in order to develop techno logy; you simply need to be
inqui siti ve, observant, and creati ve.
Whil e the ultimate goa l of techno logy is to so lve probl ems, it
can a lso create new o nes in its wa ke. For in tance, the Medi cine and
the Law editors ex plore the ethica l implications of direct-toconsumer genetic testing. With the deve lopment o f new techno logy,
we must consider how it will be utili zed, who it wil l affect, and what
furth er changes it w ill bring.

It is thus reasonable, and
nerves re li ed on changes in current.
perh aps vita l, to look beyond medi c ine for medi ca l techno logies.
We have een countless exam pl e of the impa t of tec hno logy
on med icine- e lectro ni c hea lth records, ge nomic seq uencing, robotic
surgery. Perh aps less obvious is the impact of techno logy on each
ind ivi dua l's habits and ways of thin king. T hi s jo urna l is in print
fo rm , as many peop le object to readin g off a screen. Wh y? There is
nothin g innate in our bra in that says that the printed wo rd must be
black on a white background, sized 8.5x 11 wi th page that can tu m .
If yo u handed a book to someone accustomed to scro ll s, they may
regard it with the same disda in as I currentl y reserve fo r e-readers.
As techno logy evo lves, our determ ination of w hat is no rm al or
comfortable will change. If our editors had been asked to w ie ld a n
o ld-fashi oned pen fo r thi s issue, the arti cles may have been much
briefer as they lamented the loss of the qui cker and more ergo no mi c
wo rd processer.
As thi s is my last contrib ution to the UWOMJ , I wo uld like to
thank all of the writers, fac ul ty, adverti sers, and readers w ho make
thi great pub li cation possibl e. Thi s issue ex pl ores fo rays into the
unkn own, atte mpts to ex pand o ur kn ow ledge and improve our abili ty
to hea l. To the C lass of 20 II , thi s i exactl y what we will be
attempting to do as we head off on our va ri ous res idenc ies. I urge
yo u to take the lessons of fo ur yea rs of c lini c, c lass, and camaraderie
and temper it w ith the sage advice to ' don' t stop be li ev ing.' 4
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4. Schon , Ca in J, Perry . Don ' t top Be liev in '. Journ ey: Escape. 198 1.

The introduction of techno logy can a lso he lp to legi timi ze an
a ilment by providing a solution. There are several "culture bound
syndromes," those that ex ist among certain gro ups onl y2 Severa l
years ago, the medi ca l schoo l curri c ulum would not have inc luded
erectile dysfun ction . With very few treatments availabl e, the sti gma
that shrouded this di sord er prevented many men from admitting to
symptoms. With new techniques such as those described by Kudl ow
and Radomski , the prospect of cure ha led to erectil e dys fun ction 's
recognitio n as a legitimate diag nosis.
The phrase " Hea lth Techno logy" implies a separate part o f the
whole, a branch o f study unto its own . However, innovations in a
va riety of fi e lds ha ve had an impact on medi c ine. In hi s book "The
Bra in that C hanges Itself," Dr. Do idge suggests that the concept of
bra in plasticity was initi all y li mited by the prevailing mechani sti c
v iew of the brain .3 Great ad vances were be ing made in eng ineering,
which led sc ienti sts to liken the brain to a machine. Mac hines do not
grow a nd change, thus the idea that the bra in could adapt after illness
or injury was disregard ed. With the di scovery of e lectri city, a new
conceptualization of the brain unfo lded with the suggesti on that
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The use of nanotechnology in cancer
management
Yu ding Wang (Meds 2013)*, Chanseok Rhee (Meds 2013)*, Nianxin Jiang (Meds 2013)*
Suga nt h Suppiah (Meds 2013)*, Zoya Bahreini (Meds 2013)*
*Following authors contributed equally to this paper.

Faculty Reviewer: Dr. C. Hamm (Department of Oncology, Windsor Regional Cancer Centre)
rug deli very y terns have prov ided th e phannace uti ca l
industry a means of improvi ng the th erapeuti c pro perties of
pre-ex i tin g drugs. These systems, such as lipid- or polymerbased nanoparti cles, alter the pharm aco kin eti cs and bi odi stributi on of
th e drug th at is being carri ed 2 A nanoparti c le is form a ll y de fin ed as
an eng ineered parti c le in nanometer ize. The inherent properti es of
th e nanoparti c le make it an idea l vector to di stribute dru gs. The
submi cron size, with di ameters less th an 200 nm , of th e nanoparti c le
increases its intrace llular uptake, abili ty to penetrate thro ugh
submucosa l layers and cross th e bl ood bra in barri er. 2 ·3 Both synthetic
and organic po lymers have been utili zed to create bi odegradable
nanoparti c les, like the po lylactides th at undergo hydro lys is upon
implanta ti on and broken down to lacti c ac id . The drugs are re leased
via diffusion across the po lym er matri x and through biodeg radation
o f the polymer itse l f.3 anoparti c les conju ga ted with ti ssue-speci ti c
li gand also all ow th e deli very of th e drug to be more targeted, and
redu ce th e amount of side e ffects.3.4 As a res ult, nanopartic les have
th e potential to increase the potency and e ffi cacy of the drugs th at are
a lready used in practi ce.

D

Nan oparti cle could vastl y improve th e tools we have to fi ght
cancer through a two- fold app roach: ( I) earl y detection o f cancer
and (2) can cer th erapeuti cs. The nanoparti cles target th e site o f th e
can cer for both diagno ti c and th erapeutic purpo es. The potenti al o f
nanoparti cles in th e fi eld o f oncology i ho ld many promi ses.

NANOTEC HNOLOGY FOR CANCE R DI AGNOS I S
Vari ous nanoparti cles such as ironox ide crystals, and QD emi conductor non-crysta ls, have shown great potenti a l for detectin g
di sease markers, pre-cancerou s ce ll s, frag ments o f viruses, speci ti c
prote in s, antibodi es and oth er di sease indi cators. 5
In th e fi eld o f onco logy, nanoparti c les ca n ass i t to no nin vasively detect tum ors at an ea rl y stage, perhaps months or even
yea rs earli er th an th e conventi ona l di agnosti c too ls wo uld make th e
same diagnos is, and thus res ult in max imum th erapeuti c bene fit and
improve th e progno is o f th e patients. For instance, in brea t cancer,
nanomedi c ine can potentia ll y use mo lec ular imag ing to acc urate ly
di ag nose breast ca ncer when th e tumor ma has onl y I 00- 1,000
ce ll s , a s o ppose d to th e c urre nt im ag in g tec hniqu es like
mammograph y, whi ch require th e detecti on o f more than one mi ll ion
tumor ce ll s for acc urate c lini ca l dia gnos is. 6
QDs are emi conductor nanocry tals made up o f I00- 100,000
ato ms 7 Q D conta in e lectrons, which after excitati on, can re lax to
th eir gro und state and release photon in th e proce s, lead ing to a
vis ibl e flu ore cence. The flu ore cent signa ls of Q Ds are I 0-100 tim e
bri ghter compared to orga ni c dyes and th e ir emi ss ion properti e
make it poss ibl e to overcome ti sue auto flu orescence 8 ·9 A lso,
spec ia ll y-e ng ineered Q D coated with stea lth po lymer can resi t
photobl eaching and ce llular deg radati on better th an conve nti onal
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fluo rophores (molecules capab le of flu orescence), a llowing studies to
be carried out over time. 10 Due to a ll the e unique characteri stics,
Q Ds can be conjugated to anti bodi es that have affi ni ty fo r tumorspec ific an tige ns, and they wi ll preferenti all y loca li ze to th e tumor
cell s. T he ide ntification of th e changes in ce llular surface protein
concentrati on can be an earl y ind ication of cancer. 10 Other studies
have show n that by injecting Q D-labe lled me lanoma ce ll into mice,
one can vi ua lize in vivo the m igrati on of tumor ce ll s to the lungs on
imaging. 9 T his abi lity to track tu mor mi cro-meta tas i can lead to
greater unde r tand ing of the behavior of metastati c cancer and
d i covery of ne' treatment option .
In practice, identification of th e entine l lymph node (SLN) in
breast cancer can be chall eng ing . Currently mapping is don e by using
blue dye and radi o i otope . Thi technique obscure th e urg ical fie ld
and can ca use rad iation to th e pat ient and hea lth care providers.
Superparamagnetic iro n oxide nanoparti cles a ll ows pre-operati ve
M RJ v isualization and intra-o perati ve magnetometer- aided detection
of S L , remo ing the need fo r harm ful radi o iotope and obscurin g
dyes 8
anoparti c le can a lso make importa nt advance ments in
di agnos ing and imag ing o f brain tumor , throu gh both preoperative
and intraoperati ve brain mass detecti on, a llowing for early detection
of precancerou ce ll and improv ing th e prognostic outcomes of
cancer pati ent . C urrentl y, the most wide ly u ed MRJ contra t agents
are based on paramagneti c gado linium (Gd(lll) ). 11 While still
a luabl e, th e e ion are not w ithout the ir probl ems. They tend to
diffuse freely through a tumor and pre ferenti all y image area where
th ere i prominent blood-brain barri er breakdown , prov iding limited
enhancement of th e infiltrating tum or marg in or areas of poorly
va culari zed mi crometa tas is. Al so, th e permeability of blood-tumor
barri er is not homogenous, whi ch mea n that th e ion cannot enter a ll
area o f th e tum or equa lly. Furthem1ore, thi s contrast materia l has
di ffi c ult y di c rimin atin g tum o r fro m CNS infl a mmation or
infecti ons. N anoparti cles des igned to pre ferentia ll y target tumor
areas, uch a uch as Ferum ox tran- 10, a dextrancoated iron oxide
nan? parti cle, have been developed a new MRI contra t agents to
avo 1d many o f th ese probl ems and provide a wide r window of
opportumty for tumor imag ing and enhancement. II

NANOTECHNOLOGY AS CANCER T H ERAPEUTI C
Many conventio na l cancer th erapeuti c agents work by induc ing
~e llular tox1c1ty causmg can cer cell death . Although cancer cell a re
mherentl y more susceptible to th e e ffects of these age nt , the e
agent a lso a ffect normal cell . .Tl~i s p.uts a con traint on the do age
and f~:qu e.ncy of treatment as 1t mev 1tabl y ca.uses injllly to norma l
cell s. . Th1 s constraint o fte n res ults 111 suboptimal treatment, which
contnbu.tes to the persistence and recurrence of can cer after th e
comp letiOn of chemotherapeuti c treatment. 13 Current advance 111
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nanotechnology seek to resolve these therapeutic constrai nts by
a llowing for specific targeting of cancer cell s helping to increase
drug efficacy while limiting un wanted toxicity.
Cancer specific nanoparticle directed drug de li very takes
advantage of cancer physiology by both a pas ive and active drug
de livery mechani sm. In the passive drug delivery mechani sm,
nanoparticl es are selective ly concentrated at the ite of the tumour by
the enhanced permeability and retention effect (EPR). 14 The EPR
work due to the inherent faulty phys io logy of fast grow ing tumour.
lt is known that tumours require angiogenesis for continued growth .
However, the g rowth of these new blood vesse l is di sorgani zed and
leaky due to enlarged junctions between endothelial cell as well as
defi c iencies in the underlyin g base ment membrane. 15 Whi le normal
endothelium junctions are typicall y 5 to I 0 nm in ize, 13 ga ps
between the leaky endothe lium of the tumour are signifi cantl y larger
and range from I 00 to 750 nm . 16 Concurrentl y, the di sorga ni zed
growth of the tumour a lso res ults in form ation of a disorganized
lymphatic network. 14 The leaky va culature and the lack of a
lymphatic network result in the accumulation of nanoparticles in the
cancer interstitium, passivel y concentrating dru g at the site of the
tumour. 14 Novel nanoparti cle chemotherapy, Doxil (a pegy lated
liposomal doxorubicin nanoparticle), takes advantage of the EPR. In
vitro ex periments have shown Dox il to have a I 0-fo ld increase of
doxorubicin concentration (the chemotherapeutic drug (or payload))
within the tumour compared with conventional doxorubicin
administration. 17 A lthough clinical trials comparing Dox il and
conventional doxorubi c in administration have shown no stati tical
improvement in survival (overall and disease free) , Doxil was
neverthe less shown to significantly decrease the ri sk of cardiotoxic
effects of doxorubicin use (a significant side-effect limiting dosage
and usage) . 17 It shou ld be noted that the pegylation procedure helps
the nanoparticle escape from macrophage detection 18, whi le the
lipo omal core structure helps protect the bound doxo rubicin to
achieve a significantly longer half-life than free doxirubincin a lso
contributing to the increased concentration of drug seen at the site of
tumour.1 7, 18
The active drug delivery mechanism works by targeting specific
receptors preferentiall y expressed on the tumour cell. For examp le,
folate receptors are prefere ntiall y expressed in some cancer
phenotypes whi le showing limited expression in normal ti ssue . 19
Experimental findings in mouse model s comparing conventional
paclitaxel (given as free dru g) with a heparin-folate-taxol (heparin as
carrier molecule and fo late as targeting molecule) showed the folatedirected nanoparticles to have more potent activity against tumour
growth. 12 Another example is the transferrin receptor. In vitro studies
using MCF-7 (human breast cancer cell line) comparing transferrinconjugated paclitaxel-loaded nanoparticles treatment versus free
paclitaxel showed the transferrin-conjuated paclitaxel treatment to
have greater inhibitory effect on cell growth. 20
Although drugs can be delivered to the tumour, another
significant impediment remains due to chemotherapeutic drug
resi stance. The most studied cause of resistance is the membrane
associated protein pump p-glycoprotein (p-gp) 2 1 The p-gp is
expressed in a number of cell types in the body and functions to
effectively pump chemotherapeutic agents out of the cell , conferring
resistance. Nanoparticle drug design could sidestep this impediment
by a number of poss ible mechanisms . One such mechanism is to coadminister a p-gp antagonist along with the therapeutic drug, thus
inhibiting the p-gp function. 21 Clinical trial s eva luating various
potential antagonistic agents have shown disappointing results thus
far, though new compounds continue to be discovered with improved
binding specificity to p-gp 21 Another mechani sm cou ld rely on
receptor mediated endocytosis and subsequent endosomes formation
as means for gaining access to the cell cytoplasm, which could

effectively mask the nanoparticle until a high concentration of
therapeutic drug is released to reach therapeutic effect, essentially
overwhe lming the p-gp. 12 In vitro and in vivo mouse model have
shown that drug resista nce can be overcome through thi mechanism .
21
Nanopa rti c le as a means for drug delivery offers many unique
benefits in the treatment of cancer compared to other targeted drug
therapies proposed such as ant ibody-d ru g conjugates . Firstly,
nanopa rticles cou ld carry a significantly large r drug payload per
ligand-receptor binding event compared to antibody-dru g conjugates
as we ll a being more versatile in the type of drug its ab le to carry
since drugs are stored w ithin the nanopartic le, with limited exposu re
to enviro nment, while the type and number of drugs conjugated to an
antibody cou ld ignificantly affec t its kinetics and biodistrubution. 18
Secondly, nanoparticles are large enough to target multipl e li gands
allowing for multiva li ent bind ing and se lectivity enhancement.
Therefore, nanoparti c les can use mu lti ple weak liga nd interactions to
greatl y increase the pool of cancer binding targets whereas si ng le
li ga nd recogn ition offered by antibod y- conjugates require strong
affi nity to be effective.22 Thirdly, nanoparticle des ign could allow the
rate of release to be tailored for the drug of action . For example,
topoi somerase I inhibitors such as the camptothecin-based drugs are
reversible inhibitors of the enzyme, and therefore, have better
efficacy if exposure of drug is pro longed 23 Lastl y, nanoparti c ls co uld
a llow for the co- localization of different type of agents to work
synergisticall y within the target cell to increase drug efficacy. 22
CONCLUSION
Nanoparticles hold new promise as means for earlier detection
and better treatment of cancer. Imagine a future w here nanoparticles
can help detect cancer before it even has a chance to manifest, and
se lective ly destroy cancer cells while leaving the normal cells
unharmed . Cancer, in such a ci rcumstance, cou ld become a hi ghl y
managea ble condition. However, despite our current resea rch there is
much we still do not understand. Nanoparticles offer a new avenue to
tackle these cha llenges. More research is needed in thi s promi sing
and dynamic fi eld of cancer therapeutics.
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Near-infrared spectroscopy to assess penile
blood flow: a possible novel technique for the
diagnosis of vasculogenic erectile dysfunction
Paul A. Kudlow (Meds 2013), Sidney B. Radom ski, MD, FRCSC
Faculty Reviewer: Dr. Gerald Brock, MD, FRCSC (Division of Urology, Department of Urology)

rectile dysfunction (E D) i defi ned as the consistent inabili ty
to achieve and ma intain an erecti on uffic ient to pennit
sati sfactory sex ua l perfo rmance or intercourse 1• The vast
majo ri ty of cases of ED are primaril y of organi c and vascular
etiol ogy, although psychol ogical factors also play a ro le in many
cases 1 • Affecting an e timated 2 milli on Ca nadi ans and beco ming
increas ing ly commo n w ith age, ED has been shown to compromi se
overa ll quali ty of li fe and is assoc iated w ith depression, anx iety, and
loss of se lf-es teem 2 To date, the diagnosis of ED is typi cally made
o n hi story and physica l exam 3· 4 . In recent years however, increased
understanding of the hemodynami cs invo lved in vasc ul ogeni c ED
has lead to the development of a number of di ffe rent di ag nosti c tests.
These include penil e brachial index, intracave rn ous pharmaco logic
testing, penile tumescence mo nitorin g, co lor duplex ultraso nography,
cave rno sograph y a nd ph a rmaco logic cave rn oso metry, penil e
scintig raphy, and selecti ve pudendal arteriography! · 5 Whil e each
yields inforn1ati on of some diagnostic va lue, there is yet to be a
sing le test or "gold standard" for diagnosis of EDJ Much of thi s
could be due to that fact that many of the current tests are compl ex ,
ex pensive, invasive, and often inacc urate. Given these limitations,
and es peciall y in light of advanci ng effi cac iou ora l therapi es readil y
ava ilabl e, some spec ia li sts arg ue that these tests should be reserved
for pecial cases of ED where a diagnos is is important or urgery is
required . Howeve r, an oppos ing view is that a minima ll y invas ive
and cost-effective test may till be of va lue in compl eting the
appropriate management of a patient w ith suspected va culogenic
ED6 .

E

Thi s stud y was und e rtake n to exa min e nea r- infra re d
spectroscopy (N lRS) as an approach to study penile bl ood flow and
thereby explore a potenti a l nove l diagnosti c too l for assess ing
vascul ogeni c ED. N IRS has emerged as a new techno logy within
recent yea rs for monitoring blood fl ow non-in vasive ly and sa fe ly.
The techno logy uses photons of lig ht in the near infrared spectrum to
assess concentration changes of oxygenated and deoxygenated
hemog lobin in ti ssues 6. It can provide information concerning both
oxygen saturation and re lati ve bl ood vo lume changes within the
o rgan of interest. A lthough N l RS has been w idely used to assess
muscle and cerebra l blood flo w, it use in the assess ment of penil e
blood flow has been limited 6 . We exam ined the use of N IRS to
detect pe nile blood flow and to determine if increases in oxygenated
hemoglobin (0 2Hb) concentrations corre late with erections.

METHODS
Two groups of men were exam ined. Group I cons isted of I 0 youn g
men with no erecti le difficulties, mean age 19 years (range 18-22).
These men allowed us to determine the techni ca l as pects of NIRS
monitoring on the peni s (i.e. optica l sensor placement and how to
secure the sensor) and the feas ibility of assessing penile blood flow
with visual sex ual stimulation (YSS). Group 2 consisted of 12 men

with prostate ca ncer undergo ing a bilateral nerve sparin g radical
pro tatectomy (RP). Mea n age of the patient was 55 years (ra nge
44-66) . These men underwent N IRS w ith YSS preoperatively and at
3 months postoperati ve ly w ith and wi thout 20 mg of va rdenafi l. Each
compl eted a va lidated psycho metrica ll y va lidated questi onnaire li EF
(Internati onal Index of Erectile Function) pre and postoperative ly.
During N IRS testing each man was asked to assess if an erecti on
occurred during the YSS .

RESULTS
With Group I we were ab le to create a re-usable NIRS optical sensor
probe which wa taped to the penis . In 7110 of the men an erectio n
occurred wi th YSS and wi th NIRS testing. 0 2Hb concentrati on
increased in a ll 7 men (Figure I). In G ro up 2 the mean II EF
preoperati ve core was 25 (range 5-30) and the postoperative score
was 11 . 1 (range 1-26). With N!RS testing preoperatively without
va rdenafi l, 8112 men felt they had some erect ion wi th YSS, and in
7/8 of these men there wa an increase in 0 2Hb concentrati on. In the
o ne in whi ch N IRS was unsuccess ful the erecti on was minima l. In

Figure I. Norma l ma les with good erections after VSS. Increase in
02Hb.
thi s same group, 9/ 12 men with N IRS testing showed increases in
0 2Hb concentrati on w ith YSS, 2 of which fe lt they had no erection
(Fi gure 2). When vardenafi l was g iven preoperati vely wi th NIRS
testing, 12112 men fe lt they had some erection a nd I 0/12 of the e
men had an increase in 0 2Hb concentration. Postoperati vely wi tho ut
va rdenafi l on N IRS testing 2/12 men fe lt they had some erection and
7/ 12 men we re fo und to have increases in 0 2Hb concentrati on
incl uding the 2 men that had some erection. When va rdenafil was
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added postoperati vely 7/12 men fe lt they had some erecti on and 7112
men had increa es in 0 2 Hb concentrati on on NIR te ting (5
pati ents wi th an erection and 2 wi thout). There was a rapid rise in
0 2 Hb concentration in men wi th excellent erection .
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F ig ure 2. Patient preop without vardenafil with no erection and no
increa e in 0 2Hb.

DI SC SS IO
To date, management of a pati ent with suspected ED is often centred
on a goa l-ori ented approach4•7•8 • Treatment selecti on i ba ed on
pati ent preference following a thorough di cussion with a treating
physician regarding therapeuti c options with minimal diagnosti c
te ting. Reason for this empiri ca l approach probabl y stem from the
relati vely safe and highly effective medi cati ons currentl y ava ilab le
for ED9 De pite thi s, studi e compl eted on ou tcome ana ly e of the
goa l-directed approach, often indicate low pati ent sati faction
rate JO , IJ . l2. In part, thi s could be due to the fact that without a
thorough under tanding of the et iology and pathoph ysiology of a
given patients D, commonly preferred therapi e may be ineffective.
Pe rh aps a di ag no is-based, (pathoge ne i - pec i fi e) trea tm ent
approach to pati ents with suspected ED may yield better outco mes 12
In thi preliminary tudy, we demon trated that NIR can be
used to as e
penil e bl d flow with ex ual timul ati on.
Accordingly, we perfom1ed a eries of penil e IRS studi es on both
healthy subject , and on patient presenting with va ri ou degree of
· D. Upon ana ly i , a ri se in OzHb concentratio n on N IR wa found
to correlate very well to pati ent perceived erecti ons. The results from
thi s earl y in vestigati on suggest that it may be clini ca lly u eful ~ r the
practicing urologi t. The appea l of thi s modality i further upported
by its perceived advantage : low equipment cost, tran p rtability,
operator non-dependence, simp le operati on, and sa fety
Desp ite these indi cati on for a di agnosti c role of a peni le IR
device, the criti ca l measure of the clinica l utility of any new
technology re t on its ability to direct appropri ate therapeuti c
management. Given our limited sample size, our stud y wa unable to
examine whether peni le NIRS ca n accurate ly di scern bl ood fl ow
profil e di ffe rences between vasculogenic and non-vasculogcni c ED.
Looking ahead, further studie are needed to establi sh diagnosti c
ranges that identi fy p ychogeni c/neurogeni c (non-va cul ogeni c),
mild vascul ogeni c, and severe vasculogeni c cau es of D. A we ll ,
more studi es are needed to correlate NIR te ting with Dopp ler
studies 13 •
Acknowledgements: Funding provided by niversi ty of Toronto
provided by rodynamix Techno logies Ltd.
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Surgical treatment for articular cartilage
injuries in the athlete's knee
Sandeep Dhaliwal (Meds 2013), Brennan Ballantyne {Meds 2014)
Faculty Reviewer: Dr. Marie-E ve Lebel, MD {Department of Orthopaedic Surgery)

rticular cartilage injuri e of the knee are frequently observed
in athletes partaking in hi gh-impact sports, particularly at the
competiti ve collegiate, profess iona l, and world-class leve1. 1•2
Additionally, increas ing recreatio nal parti c ipation in pi voting sports
such as footba ll , basketball , and occer has been associated with a
rising number of sports-re lated arti cular cartil age injuries in the
ge nera l popu lati on 3 .4 When left untreated thi s type of injury re ults
in long- tenn dec line in athletic perfonnance 5 and predi sposes the
The purpose of med ica l
athl ete to earl y joint degenerati on 6
inte rvention, therefore, remains twofold: I) returning the athl ete to
pre-inju ry perfo nnance; and 2) pre erv ing long- tenn knee function to
ensure a healthy lifestyle can be maintained as the patient ages.

A

Artic ul ar cart ilage is a we ight-bea rin g connecti ve ti ss ue
consi ting of chondrocytes w hose primary function is to secrete
extracellular matri x. Due to the a neural and avasc ul ar nature of thi s
ti ssue, damage caused by inju ry or pathogenes is res ults in very
lim ited abi li ty for self-repa ir7 In this manner, treatment of arti c ular
cartilage injuri es in the athl etic popu lati on presents a signifi cant
therapeuti c cha llenge. Analgesics, anti-infl ammatory medi cati ons,
activity mod ifi cati o n, change in body weight, rest and phys ica l
therapy may provide partia l symptomatic re li ef, but they do not
restore damaged cartil age to its natural state. Surgica l procedures
such as total joint replacement may he lp re li eve joint pain , but pose
significant limitations to yo un ge r patient w ishing to pursue vigo rou
physica l activity.
Additi onall y, surg ica l debridement remains a
potenti al option, but it too is not ideal as it fails to restore carti lage .
Therefore, substant ia l efforts have been devoted to the development
of biologic methods for restoring degenerating artic ul ar cart il age.
Based on the source of the cartil age repa ir tissue, new techniques can
be broadly c lass ifi ed as: 1) marrow stimul ati on-ba ed techniques; 2)
osteochondra l transplantation techniques; and 3) cell -based repair
techniques. Moreover, the development of new treatment regimens
present prom ising scie ntifi c and clinica l excitement for the treatment
of arti cu lar carti lage injury.

MARROW STIMULATION
Developed in the earl y 1980s, a su rg ical technique known as
mi c rofract ure is a cost-effective , minimally in vasive , a nd
un complicated procedure wide ly used to treat ca rtil age inj ury in the
ath lete's kn ee.
Microfracture hinges on the penetrati on of the
subcho ndral plate w ith an aw l or drill a nd filling of the cartilage
defect to take place by a blood c lot that contains pluripotent marrowderived mesenchyma l stem ce ll s.
These ce ll s pro liferate and
differenti ate to produce a cartil ag ino us repa ir ti ssue that eventuall y
fill s the chondra l defect. ·9 The procedure is carried out by pl ac ing
the pati ent in a supine positi on on the operating roo m table and
admini stering a lower extremity or genera l anaestheti c. A femoral
nerve block for postoperative pa in relief may also be used. 10 The leg
is prepped, draped and has a to urniquet appli ed which can be inflated

if arthrosco pic vis ua lizati on becomes difficult due to intra-a rti cular
bleedin g.
The orth opaed ic surgeo n ca rri es o ut a th oro ugh
arthroscopic diagnostic exam inati on whereby the lesion is identifi ed
and debrided of a ll loose or marg ina ll y attac hed ca rtil age using an
arthroscopic sha ver and a curette.
This leaves a tab le rim of
cartil age su rroundin g th e defect w hi ch is an idea l full-thickness
border to provide a degree of protection to the regenerating tissue
that w ill form in the treated les ion. 11 A ca lc ified cartilage laye r
typ ica ll y remai n
With anima l studi e showing that compl ete
remova l is cru c ial to ensure proper repa ir, 12 the ca lc ified cartil age
layer is removed by the u e of a curette or a burr. After preparati o n
of the lesion i complete, an arthroscopic aw l is e mployed to make
multipl e ho les (mi crofractures) in the exposed subchondra l pl ate.
Ho les are spaced 3-4 mm apa rt to ensure that the subchondra l bone
maintains adequate structural integri ty, and a depth of 4-5 mm , or
Until fat dropl ets are visibl y seen coming from the marrow afte r
tourniquet de fl ati on, is typically achieved .

OSTEOCHONDRAL TRANSFER TECHNIQUES
Osteochondra l gra fts of auto logo us or a ll ogenic ori g in rel y on
transpl antati on of intact mature hya line cartil age conta ining viable
chondrocytes attac hed to subchondral bone .
Although both
a uto logous and a ll ogeni c modalities represent compl eme ntary
paradi gms des igned to restore the characteri stics of nati ve ti ssue,
each pose their own set of unique chall enges w ith regard to ti sue
Generally, autografts are indi cated fo r
ava il ab ili ty and safety.
re latively sma ll (< 2cm) focal articu lar lesion of the femoral
condy les . 13 Donor-site harvest is carried out from regions of less
we ight-bea ring tructures in the knee such as the medial and lateral
trochl ear rid ge, the intercond y lar notch, or the sulc us te1mina li s of
the lateral femora l cond y le. 14
Hi storica ll y these areas were
considered non-weight bearing, but recent reports have demonstrated
that the e areas do bear significant weight and can lead to increased
donor-site morbidity, such as osteoarthriti s . 13 Adva ntages of an
auto logous ap proach inc lude immedi ate ava ilabili ty, relatively low
cost, and nonanti ge nic and osteogeni c cartil age properties that res ult
in uccessfu l osteointegration . However, auto logous graft sources
are self- limited in th ei r maximal surface area, and donor-site
morbid ity can add a sign ifi ca nt disease burden to the pati ent. On the
other hand , osteochondra l all ografts are indi cated for the treatment of
medium to large a11icul ar le ions and are hi ghl y versatil e in treating
very compl ex or multiple lesions without inducing any donor- ite
morbidity. 13 Draw backs to the allograft app roach incl ude scarcity of
donor ti ue, potentia l ri sk fo r disea e transmi sion, a well as
fin anc ia l and logisti ca l is ues regardin g graft procurement.
A utograft transplantati on can be perfonned arthroscopi ca ll y or
throug h a tandard "open" arthrotomy approach. The patient's knee
is prepped and a di agnosti c art hroscopy i undertaken to debride and
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mea ure the cartilage defect. Donor grafts are extracted using a Thandled recipient harvester. Plug sizes fo r the harvester vary from 4
to I0 mm depending on whi ch com merc iall y ava ilable instruments
are used during the operation. 14 After pl anning the number, size and
placement of spec ifi c grafts, the harvester is aligned perpendi cular to
the donor cartilage and tapped to an appropriate depth . Once tapped ,
th e harves ter chi se l is di engaged by rota tin g or " ge ntl y
toggling" (depending on which system is used) the handl e in order to
amputate the graft. The recipient ocket can be prepared using a core
or drill. In general , a socket is created in the area of the defecti ve
cartil age by u ing a slightly maller circumference T-handled
harvester tapped to a depth of equal or greater length than the donor
plug extracted.
Finally, the graft i implanted under direct
visuali zation using a delivery tube and tapping the impactor with a
gentle force. Once the graft is in pl ace, the delivery tube is removed
and any resulting margin s on the articul ar surface should fill with
fibrocartilage .
Converse ly, usi ng an open inci ion , osteochondral all ografting
commences by establi shing the size of the host knee defect using a
sizi ng cylinder. A sizer is placed over the entire les ion and a
guidewi re i dri ven through the center of the sizer perpendi cu lar to
the femoral cond yle su rface . The condyle is then scored to the
subchondral bone usi ng an appro pri ately sized circumferenti al cutter
(rea mer) placed over the guidewire. The reamer is typically drilled
into the defect to a leve l of 8- 10 mm below the nati ve cartilage
urface. 10 Employi ng the same sizer used on the host knee, the
all ograft is sized and reamed in the same area of the cond yle where
the ho t lesion is located. To avoid any height mi smatch, the graft is
carefu lly cut with an osci llating saw to an appropriate height and the
edges are sli ghtly bevelled to fac ilitate placement into the ho t
defect. Final ly, a dil ator is impacted into the recipient site in order to
achi eve sli ght dilati on (0.5 mm ) whi ch enables graft placement using
di gita l pressure. Additional fi xation can be achi eved using screws or
pins although it is usually not required with thi s method.
CELL-BASED REPAIR TECHNIQUES

Initi a ll y described in the mid-90s, autologous cho nd rocyte
implantation (ACI) plays a major ro le in treating large full-thickne
chondral injuri es. 15 AC I i a dual-stage procedure whi ch utili ze the
first- tep to harvest chondrocytes, and then a second- tep to reimpl ant them following in vitro culture. The initi al-stage involves an
arthroscopi c examinati on to enable full assessment of the inju ry to
estab li sh the patient 's suitab ly for the procedure. If it i appropri ate
to continue, sli ces of cartil age are harvested with a curet. The
femoral trochlea and intercond ylar notch are recommended a
harve t ites based on limited compli cati on and morbidi ty being
associated wi th the use of those areas.16 After the sli ces are removed
they are pl aced in a sterile vial and tran ported to the laborator;
where chondrocytes will be cultured. The second-stage of A I i
ca rri ed out u ing an arthrotomy to achi eve adeq uate exposure. The
defect i debrided with care being taken to ensure that bleeding from
the subchondral bone i minimal as it can introduce stem ce ll s and
fibroblasts into the defect. The defect is measured and a template
using steril e paper is made. A peri o Lea l fl ap from the proximal
medial tibia is obtained using the templ ate. This fl ap is harve ted
and then sutured to the cartilage rim of the defect and the border is
sea led using fibrin glue.
The cultured chondrocytes are then
aspirated into a syringe and are inj ected under the periostea l graft.1 7
CLINICAL OUTCOMES AND EMERGING TECHNOLOGY

Num erous systemati c studi es have elucidated improved knee
function and increa ed activ ity scores for all three types of arti cul ar
cartilage repai r strategies outlined above. Only recently, however,
has m~ta-analysis comparing differen t repair techniques on returning
the InJured athlete to sports participati on become available. Two
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separate reviews sugge t better outcomes for patients undergoing
autologous chondrocyte implantation and osteochondral transfer
techniques versus microfracture. 18·19 Based on a review of 20 studies
and 1363 patients, return to sports participation was observed in 73%
of athl etes with the hi ghest occurring in those who underwent
o teochondral autograft transplantation . On the other hand, 65%
were actuall y deemed to have been able to return and perform at a
pre-i njury level and thi s was best achieved with autologous
chondrocyte. 19 As it pertains to adolescent athletes, evidence in the
literature is scarce, but initial reports have suggested that better
results are observed with autol ogous chondrocyte repair.20 It appears
that numerous factor , uch a age, level of play, lesion size, and
duration of symptoms, can impact the clinical outcomes observed in
thi s pati ent popul ati on.
Several report depicting functional outcomes, 21 as well as
return to athletic competiti on 22 following microfracture can be found
in the Iiterature. Despi te initial improvements, however, there is
confli cting evi dence regarding long-term results as some studies
suggest that deterioration of knee function occurs in 47% to 80% of
athl etes 24 month s following surgery.19·21· 23 These limitations have
prompted inve tigation of new technologies to enhance the results of
ex isting microfracture techniques . For examp le, the development of
a dehydroepiandrosterone ulphate (D HEA-S)-releas ing rod that can
be impl anted into the microfractures bas shown promi se in
improving cartilage in animal model .24 Other efforts have revolved
around the addition of growth facto rs to promote chondrogenic
differentiation , or inhibiting the potential negative effects of
cytokines 23 Final ly, the creation of a bioadhesive using choindroitin
su lphate as a primary component ha yie lded promi sing re ults in
clini ca l triaJs2s
In an effort to improve clinica l outcomes, new and innovative
techniques are rapidly advanci ng the field of articular ca rtil age repair.
For instance, to avoid the problem a ociated with osteochondral
auto- or a ll ograft , yn th etica ll y manufactured bioresorbable
caffolds have been developed a ubstitute grafts2J Principles of
scaffolding have also been app lied to autologou chondrocyte
implantation \ hich pro ide a mechanism of de li ve rin g
chondrocytes into a lesi n during a ingle- tage procedure without
nece si tating ex vivo chond rocyte cu lture and expansion.26 During
th1 s procedure, the harve ted carti lage is fragmented and then
embedded into a resorbable caffo ld which is then implanted into the
knee. Other techniques currentl y being explored include the use of
g~ n e th erapy to improve cartil age repai r by tran fecting chondrocytes
w1th BMP-2, BMP-7 and IFG - 1 and neocartilage harvesting of
JUVenile chondrocytes from prepuberta l and fetal human cartilage_27
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nvented by Si r Godfrey Hounsfield in th e 1970 , computed
to mograp hy (CT) has greatl y trengthened the arsena l of imagi ng
tec hn o logies th at is ava il ab le to ph ys ic ia ns to detect,
prog nosticate, and treat d isease. T he fund a menta l prin cip le
underl ying CT cannin g is th e ex po ure of biological ti sue to
rotatin g fin e beam X- rays, fo llowed by th e detecti on and process ing
of the radi ati on th at th ese ti ssues attenuate to create a computeri zed
image 1. The two majo r types of CT scannin g are heli ca l CT and
conventio na l non-overl app ing CT. Since its introducti on, va riou
enhancements have been made to T technology which has a llowed
varied medi cal fie lds.
In cardi ac imaging,
appl icati on aero
coronary CT angiograph y has recentl y risen to the fo refront. A it i
a newer techno logy, data in th e li te rature lags behind th e well -studi ed
meth ods to qu anti fy th e amount of ca lc ium inside coronary arteri es
using infonnati on obtained from cardi ac CT scans, kn own as cal cium
scorin g 2 . ln th is arti cle, we ex plore th e use of thi s speciali zed CT
techno logy and highlight its adva ntages and limitati ons in th e
diagno i and prognostication of coronary artery di sease .

I

CT BASED CALCIUM SCORING
In coronary arteries, CT based calcium corin g meth ods quanti fy
ca lcium as a parameter tenned coronary artery ca lc ifi cati on (CAC) 3 .
Ca lc ium scoring is used to evaluate coronary artery di ease since
calc ium bui ld up in pl aques is a key process in ath erosclero is. It
sho uld be noted th at th ere is ev idence non-ca lc ified plaqu es area l o
important , however, th ey are not eva luated by thi s meth od and are
thus outside of the co pe of th is review. lectro n beam CT ( BCT)
ha been a popul ar meth od fo r th e a e sment of coronary calcium
since its development in th e 1980 . Nowadays, ca lci um scorin g can
also be perfo rm ed with multidetector or multi s lice CT canners
(MDCT and MSCT). There is some agreement that the ca lc ium
scores obta ined from both meth ods are sim il ar, th ough thi has not
Vari ous meth ods have been used to
been extensively studi ed 4.
compute ca lc ium scores ; for exa mple, th e Aga tston score ass igns a
weighted va lue ba ed on th e hi ghest de nsity o f calc ifica ti on in the
plaque and then multipli es thi s by th e area of ca lcifi cati on5. uch
scores for all ca lcifi cations in all CT li ce taken are summed up to
prov ide a CAC score for a ll th e coronary arteri es.
Due to certain limitati ons w ith Aga tston scorin g, mo t notabl y
inconsistent inter-sca nner comparability, newer methods such a th e
vo lume score and ca lc ium mass score we re developed and compared
w ith th e Aga tston score. Some studi e indi cate that th ese meth ods
m ay b e e qui va le nt t o th e Aga ts to n m e th o d in te rm s of
reprod ucibility6 . A more recent meth od of ca lc ium scorin g is kn own
as th e lesion specific calci um score in which more specifi c
parameters related to each ca lcifi ed le ion are included in th e fin a l
ca lcium score, such as w idth, density and di stance from maj or
coronary arteries 7 . T here is emerg ing evidence to indi ca te th at the
les ion-speci fi e ca lci um scorin g meth od may be more acc urate th an
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the Agat to n method fo r some purpo es; for example, the sensitivity,
specific ity, and accuracy of th e le io n specifi c calc ium score meth od
were shown to be superior to the traditi ona l Agatston core in
detecting angiographically con fi nned obstru cti ve coronary artery
di ease 8

CORONAR Y ARTE RY CALCI FI CATION (CAC) AND
CORONA RY ARTERY DISEASE
Many stud ie have shown the associati on between CAC and
coro nary artery d i ease a de tected by hi to path o logica l or
ang iograph ic methods . For example, one hi stopatho logical study on
auto p ied coronary arteri es showed th at th e EBCT ca lc ium scores
correlated we ll wi th plaque area 9 . A clin ical study of more th an 700
pati ents showed that EBCT ca lci um coring had 95% sen iti vity in
pi ckin g up ang iographica ll y ignificant coronary artery di sease 10.
CAC has also been tud ied in re lati on to myoca rdi a l ischemia.
Myoca rd ial i chem ia most often mani fe ts silentl y, and thi can be
detected as stre -induced i chemia wi th stress testin g. One studyl 1
showed that the li ke lihood of tre -induced myocard ia l ischemia
increa ed wi th a higher CAC core, a lthough the maj ori ty of patients
(78%) w ith detecta ble CAC did not have stress-induced ischemia
suggestin g a poor pos itive predictive va lue of prognosi with CAC
corin g. A report from the pro pecti ve cohort study kn own as the
multi ethni c stud y of ath e ro cle r os is (M E SA) eva lua ted the
re lati o nship betwee n CAC a nd myoca rdi a l ische mi a in a n
tudy showed that the coron ary
asy mptomati c populati on 12. T hi
va odil atory re ponse (myocardi a l bl ood fl ow w ith tre ) w a
redu ced w ith a higher CAC, but the re ting myocardi al b lood flow
was not affected by increa ed AC. These studi e provide some
indicati on th at CA may be assoc iated w ith impa ired myocardia l
perfu ion in a subclinica l ath eroscleroti c state . Ove ra ll , there is a
good body of ev idence to uggest th at CAC i assoc iated with
stru ctura l and fun cti ona l coron ary artery di sease .

PROGNO T IC VALUE OF CAC
Studi es have a sessed the prognosti c value o f CA
m both
symptomati c and asymptomati c pati ent popu lati on . There i
reasonable ev idence to indicate that AC has good prognosti c value
in asy mpto mati c pati ents. For examp le, a stud y of more th an 5000
low- interm edi ate ri sk,_ midd le-aged adu lts over a 3 yea r fo ll ow up
pen od found that h1 gher EBCT CAC sco res at ba eline w ere
assoc iated with a hi gher ri sk o f developing cardi ac events later on in
both gender 13 Anoth er study o f more than 1000 patients over a 19
month fo ll ow up period showed that higher cut-off leve l for EBCT
CA . scores we re assoc iated w ith better specific ities for predi cting
ca rd1 ac event 14 . Incrementa l progno ti c va lue o f EBCT CA C w a
observed, in addition to that prov ided by conventio na l cardi ac ri sk
factors.
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One study in a symptomatic patient popul atio n con i ting of 49 1
parti ci pants referred for coronary angiography found that EBCT
CAC scores were mode rately predictive of ang iograph ica ll y
confirmed coronary artery stenoses and that hi gher scores were
assoc iated w ith a hi ghe r incidence of coronary artery re lated card iac
events 15. A simil a r study 16 on patients referred for coronary
ang iography followed up after an average time of 7 years fo und that
among conven ti ona l risk fac tors and EBCT CA , onl y EBCT CAC
(ri sk ratio 1.72) and age (risk ratio 1.88) were predictive of future
hard cardiac events (hard events include non-fatal myocardial
infarction and cardiac death) . Furthermore, pati ents with an EBCT
CAC score of less than I 00 had significantly hi gher event-free
surviva l rates 16 . Taken together, the prognostic va lue of CAC has
been shown to have a high negative predictive va lue and a moderate
positive predicti ve va lue for major adverse coronary events (MACE).
Thus, CAC shows promise for a iding in ri k stratifi cation.

reduce treatment intensity of intermediate ri sk patients that had zero
ca lc ium scores. Furthermore, the recommendations caution against
extrapolating findings to populat io ns that have not been we ll studied ;
the ev idence appear strongest for Ca ucas ian, non-Hispanic men.

CONCLUSION
Despite some limitati ons m its spec ificity and concern s about its
app licability to pati ents of varyi ng ethni c iti es and ri sk statuses, CT
based ca lc ium cori ng of coronary artery ca lcificati on has emerged as
a useful tool that provides added prognostic and screening va lue,
especia ll y in asymptomatic patients with intermed iate coronary heart
di sease ri k . G iven the preva lence of coronary a11ery di sease and its
unpara ll e led impact on mortality and morbidity, better and innovati ve
methods of cardi ac di sease screening and prognosti cation , inc luding
ca lci um scoring, wi ll become increasing ly important in providing
patient-centred care.

LIM ITATIONS OF CALCIUM SCORJNG
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he goa l of this arti c le is to di scus DTC ge netic testing in
tenns of the process of testing, the current regul ati on of the
indu try in Ca nada and the effect the resu lting informati on can
have on manag ing individual and populati ons in hea lthcare. This
w ide-rangi ng and rapidly evo lv ing topic ex tends into the fie lds of
ge netic , ethics, law and business, each of whi ch have been
addressed in the following fash ion: the acc uracy of testing, the
predi cti ve va lue of the results, the possib le effects that the test will
have on the consumer and fina ll y the effect that the persona l ge neti cs
indu stry w ill have on phys ic ian practice and soc iety. Due to the rapid
evoluti on of the field , testing kits can now be purchased for a littl e
as three hundred do ll ars, making persona l ge netic testi ng highl y
affo rdab le and accessible.

T

THE ACCURACY OF THE ASSAY

THE EFFECT OF THE TEST RESULT ON THE CONSUMER
Whil e so me DTC co mpa ni es offer ove r-th e- ph o ne ge neti c
co unse lling with the results, it is importa nt that a ll customers
understand the information in a contextua li zed manner. Thi s require
understand ing of concepts such a re lative and lifetime risk of
di ease. Physicia ns have also ex pressed concern over so ca ll ed
' ge neti c determini m', w here the indi vidual negates environmenta l
ri sk factors which are contributory to the di sease in favour of the test
re ults8 . For exam ple, a pati ents' ri sk of heart di ea e is more
re fl ecti ve of the ir weight, bl ood press ure and/o r cho lestero l than
genetic factors 4 . A nother ethica l concern is testing for conditi ons
where there is no viab le treatment or preventati ve measures.
Advoca tes of DTC testin g po int to studies such as the REVEAL
study, w hich showed that di sclosure o f a genetic tra it predisposing
patients to Al zheimer's di sease "did not result in s ign ifi cant shorttern, psychologica l ri sks" compared to those that were not tested 9 .

DTC gene testing compani es suc h as 23andme, deCO DEM E,
Navigenics and K.no me (the ' main playe rs' in the current market 1)
are private labs governed by the laws in their jurisdiction . In Ontario
that licensing body is the Labo ratory and Specimen Co llection
Centre Licensing Act ( LSCCLA). However, the majori ty of these
corporat ions are Ameri can and are hence regul ated by the Centers for
Medi care & Medi ca id Serv ices (C MS) under the C lini ca l Laboratory
Improve ment Amendments (C L!A). Recentl y there ha s been
concern s abo ut " fau lty lab data ana lyses, exaggerated c lini ca l claims,
fraudulent d a ta , poo r c linical stud y d es ig n a nd a lack of
tracea bili ty" 2. The United States Government Accountabi li ty Office
recentl y reported that when samples of DNA were sent to four
different DTC testing companies "different compani es often provide
different res ults for identical DNA" 3 . Interestin g ly, the testing kits
themse lves are not considered medica l dev ices and are hence not
regulated by the Food and Drugs Act4.5. Additionally, the maj ori ty of
genetic tests are offered as in-house laboratory serv ices and are
simil arl y not regulated by the federal gove rnm ent throu gh the Hea lth
Protection Branch or Therapeutic Products Program 6 .

Pri vacy concern s a lso ex ist abo ut third party di sclosure of data,
e peciall y in regards to hea lth and li fe insurance, where thi s deta il ed
inforn1ation could lead to ge netic di scrimination. Whil e company
poli cy is ge nera ll y not to di sc lose information witho ut explic it
consent of the custom er, the info nnation itse lf is not protected to the
same standard as infonnatio n covered by the US Hea lth Insurance
Portability and Acco untabili ty Act ( HIPAA) 10• 11 . If a custo mer
di scovers that they are pos iti ve for a mutati on and fa il to di sclose it
to the ir insurance company, it may serve a grounds for vo iding
po licy if the insurance company finds a way to access the
infonnation 8• 11 . Sim ilarl y, the Canadi an Human Ri ghts Act does not
conta in a clause protecting aga inst geneti c di scriminatio n, thoug h an
amendment i currentl y under considerati on in the Ho use of
Commons (Bill C-536). On the other hand, Ame ri cans are protected
from such di scrimination by the Genetic Info rm ation
on di scriminatio n Act (G INA) whi ch doe not apply to Canadians using
the US based compani es.

THE LINK BETWEEN TESTED GENES AND DISEASE

THE ROLE OF THE HEALTHCARE SYSTEM

In contrast to geneti c testing in a cli nica l context, pri vate genetic
testing a lso exa mines mo re ' persona l' ge netics traits. According to
the website fo r deCODEME yo u can "di scover your ge netic ri sk for
47 di seases a nd traits rang ing from Heart Attack and Diabetes to
A lcohol Flush Reacti on and Male Pattern Ba ldness" 7 . However
di sc la imers also state the results may have poor predicti ve va lue 1 and
are not considered di agnostic, leading customers to questi on the
finan c ia l va lue of uch test res ults. Nonethe less, the e compani es
g ive the ir customers information about the research that links these
polymorphi sms to increased probability of developing a g iven
di sease.

Ontario's Regul ated Hea lth Profess io ns Act st ipul ates that a
hea lthcare professiona l i responsib le for "communicating to the
indi v idua l o r hi s o r he r perso na l representati ve a diagnos is
identi fYi ng a di sea e or di sorder as the cause of symptoms of the
indi vidua l in circumstances in which it is reasonabl y foreseeab le that
the indi v idual or hi or her per ona l representati ve wi ll re ly on the
di agnosis" 12 Does the genetic ri sk assess ment offered by these
pri va te ly owned companies count as a diagnos is? The companies
ex plic itl y state that their products are not diagnosti c o r are substitute
for medi cal advice and that a ll concern s ari sing from the test should
be referred to yo ur hea lthcare prov ider. The onus then lie on the
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fa mil y practiti oner to interpret the information, a burden that could
become substantial accordin g to a study by McGuire et al where 78%
of respondents sa id they would con ult their family doctor about
results of commercial ge netic test4 . Thi s increased burden on the
hea lthcare system is furth er complicated by the fact that famil y
physic ians are often not trained in geneti cs coun se lling and may not
be equipped to deal with thi s extensive genetic inforn1ation.
CONCLUS ION
In 20 I 0, the FDA sent regul ation letters to five American commercial
genetic testing companies stating that their device is regul ated " . . .
under secti on 20 I (h) of the Federa l Food, Drug, and Cosmeti c Ac t
(the Act), 2 1 U.S. C. 32 1(h) because it is intended for u e in the
di ag nosis of di ease or other conditions or in the cure, miti gati on,
treatment, or preventio n of di sease, or is intended to affect the
tructure or function of the body."; it went on to state that the product
is cia sift ed a a medica l device under the Medi ca l Device Act and as
such require premarket approva l13 Increas ing regulati on has been
occurring in both the United tates and many European countries out
of concern for inaccurate or mi leadin g test results 14

11 . Wolfberg, Adam J. Ge nes on the Web - Direct-to-Consumer Marketing of
Genetic Testing. ew England Journal of Medicine 2006;35 5(6):543-545.
12. Regulated Health Professions Act Section 27.2. 199 1, bttp://www.elaws.gov.on.calhtm Vstatutes/english/elaws_statutes_91r 18_ e.htm .
Accessed December 20 I0.
13. Food and Drug Admina tration : Letter to Industry. http ://www.fda.gov/
Medi ca iDevices!ResourcesforYou/l ndu try/ucmllll 04. htm . Accessed
December 20 I0.
14. Hogarth , Stuart, Javitt, Gai l and Melzer, David. The Current Land cape
for Direct-to-Consumer Genetic Testing: Legal, Eth1 cal, and Policy Issues.
Annual Review of Genomics and Human Genetics 2008;9: 16 1.

However, supposing the tests are accurate and re lati ve ly spec i fie
the next logical question is whether the knowledge of ri sk factors
will translate into better outcomes for patient : reduci ng risk, ea rli er
creening, prophylactic measures and, in orne cases, influence on
fa mil y planning6 . It i difficult to assess thi s as the industry is
relatively new and there is no follow up after the company di close
the re ult to the customer. Without counse lling it may be difficult to
put the ri k into context for the indi vidual pati ent and an over or
underesti mati o n could be de lete ri ous to a pati ents' hea lth4
Proponent argue these te t champion patient autonomy and to limit
access to one's own genome is paternalistic whi le detractors are
concerned the patchwork regul ation does not protect customers
purchasing these products. With expanding use of these services the
effects of thi s pl ethora of informatio n, both posi ti ve and negati ve,
will be become more apparent.
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s healthcare costs escalate and the public maintains high
expectat ions abo ut health ervice delivery, the sustai nabi li ty
of our current public system ha become untenable. In 20 I 0,
health expenditures compri sed 11.7% of Canada 's GOP and 192
billion dollar were spent on hea lthcare. 1 Furthermore, Canada 's oftcited agi ng popul ati on-which consumes 44% of a ll hea lthcare
do ll ars-continues to grow. In 2005 , 13% of Canadians were age 65
or o lder; by 2036, that figure is expected to reach 24.5% 2 As
policymaker struggle with broad healthcare reform, they are asking
hard questions abo ut the margi nal returns of further spending on
sickness care. For their part, c lini ca l managers and c lini cian- leaders
are worki ng to reorgani ze the delivery of hea lth services, promote
evidence-guided decision-maki ng, and create a culture of interprofessiona l co ll aboration and qua li ty improve ment.

A

There is increasing pressure to promote cost-efficiencie in the
hea lthcare system, and hea lth information techno logy (IT) has
enormous potential in that regard . Ev idence suggests that such
innovations can enhance the effic iency, cost effectiveness, quality,
and safety of hea lthcare delivery.3 A nd as the face of hea lth human
resources c hanges, with the adopti o n of co llabo rative multidisciplinary models of care, sharing of health information between
providers is all the more cru c ia l.
As of March 20 10, an e lectronic hea lth record is ava ilable for
22% of all Canadi ans, and by early 20 II , that proporti on is predicted
to reach 50%. 4 Canada Hea lth lnfoway is an orga ni zation charged
w ith managing the development, and promoti ng the adopti on of,
electroni c health record systems in Canada; its goa l is fo r a ll
Canadians to have an e lectronic hea lth record by the year 20 I 6.
When we compare o urselves to peers in other nati ons, it is clear that
we are not keeping pace. In 2006, Canada ranked last amo ng seven
countries based o n the use of hea lth IT by primary care phys ic ians.5
According to a survey of almost 1500 Canadian phys icians, onl y
37% use hea lth information technology. The statistic for our hos pital
is more optimi stic: approx imately 65% have at least one e-hea lth
compo nent. 4
What makes this task so daunting? The complex ity of hea lth
informati on techno logy lies in the amount of data, the sensiti v ity
(and need for pri vacy) of data, and the hi gh stakes in ensuring the
accuracy of data. Banking is an indu stry with simil ar infom1ati on
technology needs; according to data fro m 2004, US financial services
spend 5.4% of their tota l budget on information technology. It is
therefore no surpri se that we have a long way to go : the ave rage for
Canadian hea lthcare IT spending was onl y estimated at 1.5-2 .0% 6 In
thi s review arti cle, we will di scuss both the potenti a l benefits and
challenges to widespread hea lth IT implementati on, a we ll as
provide recommendations and future directi ons for the fi e ld .

BENEFITS OF HEALTH IT
Hea lth in formatio n technology can deliver a wide range of benefits,
including system-leve l effic iencies (reduced co t and increased
productivity), better de li very of care, improved pat ient safety, more
effective communi cati on between providers, and increased access to
inform ati on. Whi le we have categori zed benefits for the sake of
discussion in thi s arti c le, we recogni ze that these benefits are not
truly di screte, and are actua ll y inter-re lated; for exam ple, when
prov iders communicate mo re effective ly, the resulting decrease in
ambiguity leads to improved patient safety, and ultimately, a costefficiency through do ll ars saved treating an adverse event.

Enhanced productivity and long-term cost savings: From an
efficiency perspective, upgrades to healthcare IT can he lp minimi ze
wasted time and reso urces in a c linica l setting. For example, the
e limination of paper charts increases the amount of physica l space
that can be used for patient care. Furthermore, computeri zatio n of
medi cal records leads to reduced storage and transcription costs.
After a period of training and adj ustment, e lectro nic documentation
of clinica l encounters wo uld be more rapid than hand written
documentation in a paper chart; as such, the amo unt of time that
c lini c ians spend on admini strative tasks is reduced, freeing up
va luabl e time for producti ve c lini cal care. A sing le e lectronic pati ent
record can res ult in smoother ha nd-offs and ti g hter connections
between health providers along the continuum of care, leadin g to an
overa ll more efficient care process . Furthermore, hea lth infonnation
technology can be used to optimize the scheduling of procedures and
diagnostic tests , reducing overbooki ng and bottlenecks, thus
all ocati ng resources mo re accurate ly.7
The costs of imp lementing a hea lth infonnation strategy are
hi gh. However, evidence suggests that the payoff can be equa ll y
impress ive. In Canada, for exa mpl e, the estimated productivity gains
and savings from a full y implemented electroni c hea lth record are
estimated at 6 billion 4 There is a growing body of literature that
presents detailed cost-benefi t analyses of hea lth IT impl ementation .
One study 8 used US data to demonstrate potential net efficiency and
safety savings of $8 1 billion each year, after wi despread and
effective e-hea lth adoption. These ga ins in efficiency wi ll ideall y lead
to the transfer of labo ur to more producti ve activ iti es. The authors
analyzed other industri es for productivi ty ga in s as a result of
widespread IT implementati on, and estimated potential gai ns for
hea lthcare between 1.5 and 4%.
Another paper9 assessed the va lue of a fully standardi zed and
interoperable nationwide health IT system in the US. Des pite the
hi gh co t associated with this ambiti ous task (estimated ten-year
ro llout co t of $276 billion), the authors projected a net value of
$77 .8 billi on annua ll y afte r implementation is compl ete. A third
study 10 perfom1ed a cost-benefit ana lys is of an ambul atory care
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electroni c medica l record ystem, and e timated the net benefit for a
5-year period at $86,400 US per provider. Financial be n~ fit were
largely realized from aving in drug and radi ology expenditures, and
improve ments in reimbur ement (reduced bdlmg error and ,
accordingly, better capture of charges).
Enhancing the delivery of safe, high-quality patient care: The
Canadi an Adverse Events Study tabul ated 70,000 adverse events that
occur in our ho pitals each yea r, resulting in as many a 23 , ~00
death .1I British Columbia ha implemented a drug mformatwn
ystem (DI ), wi th great uccess: if the e results are used to make
projecti ons for all of Canada, we can ex p~ct an electromc DI S to
reduce inappropriate pre cription by 55 million , and to 1dent1 fy 20
million drug interactions.4 Thi s positive impact on patient afety can
al o translate into cost-savi ng . In one tudy, adverse drug event
were a sociated with an increase in co t of $2,262, primarily due to
a 1.9-day increase in length of stay. 12 Data cited in another rep~rt7
sugge t that drug-related event cost the average 200-bed h p1tal
between 1.6 milli on and $3 milli on a year.
The potential for health in fo nnation technology to reduce er:ors
i three-fold : by preventing the error upfront, by alertmg clmJCJan
and all owi ng a more rapi d correction of the error, and by reportmg
and generati ng feedback about the adver e event.D In a controll ed
trial eva luati ng the effect of computenzed med JcatJ on o rd e~ e nt ~ by
phy ician , the in e tigator found a 55 percent reduction 111 .s~ n o u
medi cation errors; a follow-up tudy later eva luated the addJtJon of
enhanced leve ls of clini cal deci ion support to the electromc
appli cati on, and noted an 83 percent reduction in the overall
medi cati on error rate. 14 A fundam ental advantage to electroniC health
reco rd s is th e elimin ati on of i ue that pla gue written
documentati on, such as ill eg ibl e handwritin g and in compl ete
medi cati on orders. Communi cation breakdowns, most notabl y dunng
poor "handoff" between clin ica l team members, are ano.ther
common ri sk factor for adver e events. 13 Hea lth IT can facilitate
effecti ve communication among providers, particu larl y wi th the u e
of hand-held wire le s device wi th access to the electroni c patient
chart .
The capaci ty fo r electronic information systems to facilitate
effecti ve clini cal decision-making is increasi ngly being recogni zed.
Order entry system ca n limi t do age or route of admini !rat ion for
potentially un afe medi cati on ; for exa mpl e, in patient with rena l
dy func tion , com puterized ca lcul ati ons of safe drug dosage . are
particularly beneficia l. 13 IT can peci fically improve pati ent
monitoring. For exam pl e, IT y tern ca n alert clinic ians to
potentially eriou lab atm rma liti e that may otherw i e be
overlo ked , and promote earlier c rrection : in one trial, this strategy
decrea ed the duration of dangerou patient cond itions by 29 percent.
15 In a related approach, technology-enabled remote monitorin g of
inten ive care lead to a reduction in mortali ty of up to 68 percent, and
a reducti n in average length of stay and associated costs of abo ut 33
percent. 16 Fin all y, hea lth informati on technology can increase linkage
to clini ca l reference and best practi ce reco mmendati ons, all ow in g
clini cians to make ev idence- inform ed dec ision .
Increased access to information: Increas ing acce s to informati on
leads to myriad benefit , at th e leve l of patients, provi ders, and the
hea lth y tem alike. Many of these benefits have already been
rea li zed by prov incial initiati ves. 17 Fir tl y, provi ders ca n deve lop a
common understanding of pati ent conditi ons, leading to more
sea ml es care for patients. For example, ON Mail is an email erver
that all w for transfer of pati ent medi ca l record back to the family
physician upon di scharge from a hospital. Currentl y, 55,000 Ontari
hea lthcare wo rker have ONE Mai l accounts. 17 Secondly, hea lth
informati on technology ca n also facilitate communi cati on and
co ll aborati on between prov iders, whi ch i parti cularl y relevant to the
en hancement of rural hea lthcare deli very. One exa mpl e, Tele troke,
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is an emergency telemedi cine app lication that uses..two-w.ay
communication and digital imaging to connect local phys1c~an s w1th
remote neurologi t located at large urban centers, to ob~m urgent
di agno is and treatment reco mmendat.ions about the1r stroke
. t Tllus •ar 1200 pati ents have rece1ved urgent care that saved
pat Jen s.
" '
. .
d d d
I
t 1e11· . 1·1ves. 11 TJ1irdl y, when health informatiOn IS share
· · ,bre un
fi ·ancy
1
and the need for duplicate testing are decreased ; th1s IS ene JCJa . to
patient , who wi ll no longer have to undergo. unnecessary repet1t1on
of te ts, and a a ystem-wide co t-effic1ency s m~e additiOnal
ex pen ive te ts can be avoided. A local s ~ ccess story 111 th1 s arena,
the South Western Ontario Digital lmagmg . etwork (SWOD~)
pro ides regional hea lthcare providers electroniC ac~ess to a pat1 e n~ s
medical imaging result , when taken at any hosp1 tal 111 the network. 7
tories, there a.re other intriguing
Beyond the e to at ucce
potential outcome of increased access to health mform~t10n . In o~e
cena rio, where patients are to rece1ve access to the1r electrom.c
hea lth record, they could use this informat1on to manage the1r
chro ni c conditi on on a day-to-day ba i , identi fy ri sk facto r , and for
self-care . One important benefit that can be felt on both a systemand patient-level i reduced wait times . The u e .o f hea lt.h IT to ~a
ord inate and manage wait lists, and to make \ a1t time mformatwn
acces ible to the public in real time, i well document~d. In the UK,
for examp le, their national health sy tem reports wa1t t1mes .data that
uch, patient can make an mforme.d
i le than one month old.18
deci sion about where to go for care. A related benefit of hea lth IT 1
the wea lth of data that are made readily avai lable; this is u efu l both
for reporting of health tatu to the provi ncia l government, and for
reporting of performance indicator (e.g. length of stay and mortality
rates) to increa e h pita! accountab ili ty.
BARRJERS TO

UCCESS

One reviev 3 provided a uccinct classificati on of four types of
barrier to the implementation of health information technology.
ituational barrier include time and financial concerns; cogniti ve
and/or phy ica l barrier include phy ical di sabi liti e and in ufficient
comp ut er kill ; liabi lit y barriers include co ncerns a bout
confidentia lity; and kno\ ledge and attitudinal barrier include
apprehen ion about change or lack of awarenes of potential benefits.
With re pect to financial concerns, it is no urpri se that
wide pread hea lth information technology implementation come
with a hefty pric tag. The co t of impl ementation include oftware
and hardware, training, work Oow proce s redesign , hi torica l paper
chart ab tracting, and ongoing maintenance and upport. There are
al o indirect co t as a re ult of the transition from a paper to
electronic y tem , uch a the temporary decrea e in provider
producti ity after implementation, a they adjust to a new y tern . IO
The creation of an electroni c hea lth record for all anadian is
projected to co t 10 billion. 4 In Ontario alone, thee timated total
cost of a three-year e- hea lth trategy- which focu e on diabetes
management, medi cation , and wa it times- is over 2 billi on. 19
Compounding thi s hi gh co t is the fact that the pre um ed financial
payoff is delayed: one rev iew including 82 studi es with co t-benefit
analyse bowed the time to break-even on hea lth IT in ve tment wa
between 3 and 13 year .3 In some cases, the fina ncial payoff may
also be uncertain- particularl y for physicians operating in a mall
group or olo practice, where the return on in vestment i le
ub tantial, and there i no forn1a l organi zati onal upport for training
and re tructuring.20 Moreover, the ta k of performing a co t-benefit
analy i can it elf po e diffi culti e , given the chall enge of a igning
do ll ar va lues to producti vity ga in or improvement in pati ent ca re.
With re pect to attitudinal baJTier , Poon et aJ21 noted the
percepti on that hea lth informati on technology could have a negati e
impact on clini ca l proce se . Thi s pea ks to the fact that technology
ca nnot be applied to a clini ca l area without careful workO w
analy es; where nece sa ry, updated protocol hould be implemented
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that are in sync w ith the new techno logy. The authors 21 a lso noted
that product and vendor immaturi ty was a barri er; many c urrent
software offerin gs were not compatibl e w ith hospita l needs, and
va ri ous modifi cati ons were necessary to acco mmodate th e hospita l's
current workflo w.
Hersh22 reported that system and data interoperability was a
major concern , noting the " info rm atio n s ilos" pervas ive in manag ing
healthcare data. Further to thi s, sma ller, pil ot proj ects are o ften more
affordable, and thu s, des irabl e from a manage ment perspecti ve; this
becomes a probl em when a hea lth system has multipl e incompatibl e
e lectroni c medi cal records, and an ex pens ive standardi za ti on process
must be undertaken. Hersh22 al o identified the need for a wo rkforce
tra ined suffi c ientl y in c linica l in formati cs to ro ll -out such a compl ex
implementati on process. A re lated cogniti ve barri er is the lack of IT
kn ow ledge and tra ining in hea lth profes iona l edu cati on; thi s can
certa inly impede fro nt-line c lini cian ' acceptance of techno logica l
trends in their wo rkpl ace.

CONCL USIONS
Recommendations: A n e lectroni c hea lth inform ati on system has a
large impact on the day-to-day wo rk of both c lini c ians and hospita l
admini strators. As such, there i a c lear need to engage, and ensure
buy-in from , these stakeho lders ea rl y in the dec ision process 7 Health
profess iona ls in particul ar should be con ulted in order to e lect and
build an e lectroni c system that i compatible with clinica l needs and
patient fl ow. One approach i to des ignate key phys ic ians as
"champions" of the process, w ho can then help moti vate other
clinicians and admini strators, and promote acceptance and adopti on
o f the IT system 7 Often times, there is res istance among front-lin e
staff when a change is seen as coming fro m admini strato rs who are
not fa miliar with c linica l processes; if the process is supported by a
res pected c linical co ll eague, however, other c lini cians tend to be less
wary. It is also important not to underestimate the sca le o f such an
implementation process . The process ma y inc lude modificati ons to
the software architecture and the establi shment of new standards of
care or changed medi ca l practi ces. C hange management itse lf
requires reso urces and time; for exampl e, in one Canadian hospital
system , app rox imate ly 30 percent of the tota l proj ect budget was
allocated to thi s stage. 7 Another approach is to implement an
infonnation technology ystem in a succes ion of phased pil ots; the
proj ect team ca n identi fy lessons learn ed and apply them to
subsequent ro llo uts. If pilots are successful , other clinical areas w ill
be eager to undergo the same change. Increas ing education and
awareness about the benefits of hea lth information techno logy w ill
boost acceptance of change on the part o f the ge neral publi c and
health prov iders alike. Data eluc idating these bene fits are required
for such endeavours; c lini ca l settings w here IT systems have been
implemented should be encouraged to co llect, analyze and publi sh
data on the results. Finall y, hav ing di verse applicati ons and softw are
platform s increa ses co mpl ex ity, ra ises costs, and le ngth e ns
implementation timeframes. 7 As such, at a time of rapid adoption of
health IT, it is crucia l to impl ement a simple, unifi ed system. It will
be important to ma intain an integ rated e-H ea lth Ontari o strategy to
facilitate this .

The path ahead: Health info rmation technology has created endless
opportunities and has enormous potential to transfo rm the de livery of
healthcare. The possibilities even surpass the bi o medi cal model: an
e lectronic health record has the capac ity to link c linica l data to
indicators of soc ioeconomi c statu s, a ll o win g a re ma rkabl e
understanding of the impact of soc ia l determinants of hea lth .
However, this chang ing landscape has also challenged us with
important questions. 18 Who will have access to thi s wea lth of
infonnation? Will patients be able to v iew the ir own e lectro nic
record? If data are anonymi zed, are they then ethica l for gove rnment
reporting and public use? Will health info rmatio n techno logy be used

to increase transparency, by provid ing o utco mes data to the ge nera l
public? Will c lini cia ns fee l comfortable operatin g in such a system,
where the ir post-operati ve morta lity rate is wide ly publi shed? And
perh aps most importantl y, will the myri ad stakeho lders em brace the
opportuni ty to co ll aborate and use infonnati on fo r the ad va ncement
of hea lth? We look forwa rd to leamin g the answers to such questi o ns,
and hope that innovatio ns in hea lth in fo rm ati on techno logy w ill be
embraced ac ros Canada.
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i ky sex ual behaviour among adole cents is a ignifi ca nt
ca u e of infection and morbidity, as well as un wa nted
pregnancy. In the United State , 25% of females between
14-1 9 have acquired a ex uall y tran mitted infection (STI) and
adolescents between I0-24 account for more than 20,000 new cases
of HIV/AIDS annually.1 While many ST I are eas ily treatabl e, they
can also lead to pelvic infl ammatory di sease, chronic pain , or
cervica l cancer and infertility.2 As we ll , there are over 745,000
teenage pregnancies in the US every year.1 Therefore, promoting
se ual hea lth through yo uth - pec ifi c interventions is an important
topi c of research and concern .

R

In the past, sex ual hea lth promotion interventi ons (S HPI ) have
been provided through choo l programs and sexual hea lth clini cs.
Through thi s medium, informati on is typica ll y given face-to-face by
hea lth care workers and is compl emented by print materi als. Whil e
these trategies have hown moderate succe , they are limited by
cost, time, and access ibili ty.3 Face-to-face HPI have not been hown
to ub tantia ll y impact Tl in fecti on rate , unplanned pregnancy
rates, or number of sex ual partners, although they have been shown
to increase knowledge abo ut sex ual hea lth and condom u e.3 Th e
introduction of new techn ology all ows for a less ex pensive and more
effi cient way of pro moting sex ual hea lth to the largest number of
peopl e. Th e most successful technology-ba ed SHPI to date have
involved eith er internet-based interventions or tex t-messaging-based
interventions. Since 93% of U adolescents have a computer at home
and 85% of 14- 18 year olds own a cell phone,4 these media prov ide
exce llent access to the adolescent popul ati on. Techn ology-ba ed
SHPI have not onl y been shown to reduce ri sky ex ual behav iour and
increase know ledge of sex t.ml hea lth ,3 •5•6 but ca n reduce co t and
time spent by hea lthcare workers by shifting the burden to more
automated technologies 7
Sex ual hea lth pro moti on con i ts of prov iding indi viduals with
the too ls to make informed dec i ions about their ex ual we ll -be ing. 3
The overall goa l is to improve the sex ual hea lth of a popul ati on
through commun ity- based interventi ons. In order to do so, however,
one mu t first identi fy th e reason that ind iv iduals, espec iall y
adolescents, engage in ri sky sex ual behavio ur. Recent research into
adolescent moti vation fo und that the fo ur main factors that contri bute
to these behaviours are: low percepti ons of ri sk, lack of confidence,
the influence of social norms, and in accurate knowledge.s Most
interventi ons ai med at adolescents focus on thi s last factor by
providing information on Tl and contrace pti on; however the e
strategies have show n onl y margin al ucces .2 Sex ual hea lth
promoti on interventions must not onl y focus on bi ologica l outcomes,
such as STI incidence rates or teen pregnancy, but on behav ioural
and emoti onal outcomes - in creased self-e ffi cacy, moti vati on to
change, and confident dec ision-making.

20

Technology-ba ed strategies can incorporate thi research by
prov iding populati on- peci fi e interventi ons that touch on multiple
a pects of ex ual hea lth . Studi es have shown that interventions are
more effective when they are ba ed on behavioural theori es and
address th e soc ial and p ychologica l cau e of risky sex ual acti vity.5 •8
lnte rn et-ba ed and text-me aging-ba ed interventi ons have the
abili ty to promote behavioura l change by u ing the con venience,
peed, and ubiq uity of these techn ologies to access at-ri sk
adolescents .
lnternet-ba ed HPI are promi ing because they a llow for
anonymou , repeatable, con enient, and inexpensive interventi ons
that can reach popul ati ons that are more res istant to mainstream
medi ca l ca re 3 Almo t 50% of youth urveyed have already used the
In te rnet to search fo r sexual hea lth in fo rmati on.5 A recent Cochrane
Rev iew meta-analysis of interacti ve, computer-ba ed HPJ found
igni fica nt effect
n both behavioural measurements, uch a
condo m use, and psychologica l mea urement , such a confidence
and elf-efficacy3 . Fifteen RCT \ ith 39 17 part ic ipant were
reviewed. In keeping wi th pre ious fi nding on the importance of
moti vation and dec i ion- mak ing in behaviour modification5 , the
review focused only on interventi ons that required user contribution
and provi ded perso na lized fee dback. T he mo t ucce ful
interventi on were tai lored to an indi vidual's leve l of know ledge and
invol ed role-playi ng or ituational exerci es. 3·4.8.Q.JOStudi e that
foc u ed specificall y on adole cents were also more ucce ful if they
a oided negati ve me ages and scare tacti cs, and ta rgeted peci fi e
behaviour . Many of the e interventi on exempli fy the principles of
hea lth promoti on becau e they not onl y educate, but al o prov ide
u ers with the confi dence and motivati on required to make safe
dec i ion in the future. 1 Other we b ites prov ide user with
anonymous and acce ib le way of improv ing sex ual hea lth ia mailin Tl te ts or onli ne contact-trac ing after Tl diagno i .1
Us ing text messag ing to promote adolescent sex ual hea lth has
many adva ntages . Tex t mes ages are fast, co nveni ent , and
inexpen ive; they can be sent to multiple indi viduals at the ame
tim ; they. are very popul ar among adole cents, and text mes aging
rate are unil ar bet~een socioeconomi c groups.6 Tex t me aging has
been Incorporated 1nto ex ual hea lth ca re in numerous ways, with
encouraging res ults: Sex ual hea lth clini cs in the UK have begun
prov1d111g results of Tl tests via tex t mes age if des ired - 70% of
adolescents preferred thi to booking a foll ow-up appointment. ? The
UK ha . a l ~o . begun a text mes aging "G rab a Condom" campaign,
where mdJ v1dual can request condoms and have them homedeli vered6 Other clini c have begun prov iding daily text mes age
remmders to pat1 ent about taking oral contraceptives, and have seen
a ignifi cant improvement in reported co mpli ance6 The most
prom1 mg interventi on, implemented
in an Franci co aiiO\
indi viduals to text " XINFO" from any mobile phone and r~cei e
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infom1ation about sexual hea lth , relati onships, and nearby clini cs. In
the fir t 6 month , SEXINFO rece ived more th an 4500 tex t mes ages
and th ose who remembered seeing adverti sements for the ervice
were ignifi cantl y more likely to be concerned about STI . 11 Wh ile
not yet widely used, tex t messag in g shows promi se a an effecti ve
SHPI that can be u ed to target adole cents directl y.
The use of technology-based HPI is relatively new, although
their effectiveness has been demonstrated in numerous tudi es.
However, there are till concem that th ese strategies may be aving
time and money at the ex pense o f acc uracy and hoi isti c care. A recent
study of 177 sexual health website showed that 17% contained one
or more medica l errors, and the number of errors was correlated with
the complexity of the topi c at hand. 12 Sex ual hea lth web ites foc u
strongly on ST is and contracepti on, but often only contain a cursory
treatment of how to ex press sexuality, body image, and th e po iti ve
aspects of sex. 13 A recent stud y of 30 " Positi ve Youth Development"
interventions- tho e that foc used on empowerment of di adva ntaged
youth - howed that all ucce sful in terventi on in vo lved a
supporti ve environment containing pa rents, teachers, or hea lth ca re
providers. 1 Can technology-based interve ntions provi de thi s ame
level of support and intimacy? ea rl y half of teenager cited their
parents a the people with the most influence in their sex ual dec isionmaking, yet very few of the intemet- or text mes aging-based
interventi ons encourage parental in vo lvement. 5 Moreover, prov idi ng
STI results via text messaging led to a decrease in foll ow-up visits,
which wa hail ed a a succes by the UK sex ual hea lth clin ics
invo lved . 14 Howeve r, if th e e in te rve nti o ns lea d to fewe r
conversation between adole cent and their hea lth care prov iders, is
this reall y omething to ce lebrate?

for global diffu sion. urr Opin Psyc hi atry. 20 I 0 Mar;23(2 ): 139-44.
8. Bull
, Phibbs . Watso n , Mc Farl ane M. What do yo un g adu lts expect
when they go online? Le on for development of an TD/HIY and
pregnancy prevention web ite. J Med Sys t. 200 7 Ap r;3 1(2): 149-58.
9. Ki ene M, Barta WD. A brief indivi duali zed co mp uter-d eli vered ex ual
ri sk reducti on intervention increa es HI Y/AID preventi ve be hav ior.
Journal of Adolescent Hea lth 2006 ;39( 3 ):404- 10.
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Journal of Hea lth Co mmunicati on 2007 ; 12( I ):53- 76.
I I. Le vine D, McC right J, Dobki n L, Wood ru ff AJ, Klausner JD. EXTNFO: a
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Health. 2008 Mar;9 (3 ):393-5.
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yo ung peo pl e. J Adolesc Hea lth . 20 I 0 Aug;47(2) :206-8.
13. Ge rress u M, French RS. Using th e Intern et to promote ex ual hea lth
awa reness among yo ung peo ple. J Fam Plann Reprod Hea lth Ca re. 2005
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Medi a and communi cation techn olog ies, like Internet and text
messaging, have the potential to be used as fa r-reaching and costeffecti ve method of promoting sex ual health among adolescents.
Initi al studi e demonstrate that the e intervention can successfu lly
provide know ledge, motivate people to change behaviour, and
encourage adolescents to seek medica l ca re when necessary.
However, few studies have measured their effect on long-term
outcomes, uc h as ST I in fec tion or pregnancy rates. As we ll, some
concem remains that technology-based SHPI cannot full y address the
emoti onal needs of adolescent in the sa me way a face-to-face
conversations with a hea lthcare provider. Neve11heless, it is th ought
that reaching adolescents "on their own turf' , by using medi a th ey
are comfortabl e and fa miliar wi th , may encourage them to seek care
when nece ary and fee l more motivated to practice safe sex ual
practices.
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he compl ex orga ni zation of the Canad ia n healt h care system
has led to fragmen ted care, and cha ll enges in interdi sci pli nary
communicati o n. Adva nce in techn o logy, however, are
rapidl y e nh anc in g th e potenti a l fo r multipl e di sci plin es to
communi cate and integrate infonnati on. Many of th ese adva nces
have been fostered under th e leadership and influence of radi ology.

T

Innovati on i described as hav ing two components: th e
development of new technologies, and th eir adoption into c lin ica l
practice 1. Both are req uired fo r a rea l impact in med icine. Beginning
with Roentgen 's discovery of x- ray , inn ovat ion in new imag ing
techniques like ultraso und, CT and MRI ha pro pelled radio logy to
th e fo refront of cutti ng edge med ica l science. Furthenn ore, leaders in
radi ology have pi oneered efficient communicati on and electroni c
storage strategies to more effi ciently adopt th ese imag ing modalities
into c linica l practi ce, accessibl e to a large r group o f caregive r 2
Pi cture Archi ving and Communicatio n System (PACS) is ju t one
example th at has now been implemented in hospita ls acros th e
country and throughout the world .
The fi eld of radi ology has been exempl ary in using innovati on
to fac ilitate multidi sc iplinary care. O ften, however, th e e innova ti ons
are adopted or compl ete ly taken over by oth er pecialti es res ulting in
" turf wa rs", whi ch create animos ity, hinderin g co ll aborati on on a
fund amenta l level. In additi on, it is poss ible th at ince techno logy ha
redu ced face- to-face time in non-medi ca l rea lms (e.g. Face book,
online chat, bl ogs), it could a lso negati vely impact communicati on in
medi c ine. Thi arti c le arg ues, however, th at an increase in
compute ri zed co mmuni ca ti o n is a pos iti ve deve lopm ent fo r
inte rdi sc iplin a ry co ll a bo rati o n owi ng to th e nature o f th e
techno logies used . Thi s arti c le w ill a lso outline so me exa mpl es of
current techno logy th at have co me to ymbo li ze th e concept o f
computeri zed clini ca l integ rati on.
Despi te literature th at bemoa ns th e decrea ed c lini ca l pre ence
of radi o logists caused by technology, its adva ntage to pati ent care
ca nn ot be ignored . A radi ologist stated, " th e say ing 1empora
mulantur is as tru e today as it was in th e day o f th e Roman : time
change, and we must change w ith th em" 3 . Radi o logists have been
pi vota l in deve loping these modern techno logies and now must adapt
to best rea p th e ir rewa rds.

PICTURE A RC HIVING AN D COMMUN I CATI ON SYSTEM
PACS re fers to the e lectroni c storage of multimoda l data
in c lu din g imag ing studi es, repo rts and pati e nt identifi ca ti o n
in fo rmat ion. PACS repl aces hard co py data ( film s and paper records)
and all ows th e integratio n of imag ing with oth er systems such a th e
Electroni c Medi ca l Record (EMR). There are severa l storage form at
fo r PACS, whi ch a ll ge nerall y inc lude images (w hi ch can be T,
MRI, US, PET, endoscopy, mammograph y, oph th almo logy, etc), a
secure netwo rk, multip le wo rkstati on (w hi ch can ex ist at mu lti ple
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ho pita ! si te ), and patie nt archives . PACS fac ilitates remote access,
and is u ed by ra dio logists to perfonn te leradi o logy, or off- ite image
in terpretation. Integrated into PAC is a wo rkfl ow management
system, which a llows fo r an efficient a yn chrono u communicati on
ys tem 4 . In other wo rds, once the image is acquired , pre liminary
comments can be made by the technic ian or referrin g phys ic ian. In
addi tion, if a diagnos is is made immedi ately and acted upon, say in
the ED, thi is recorded and can be later re-eva luated by th e
radi ologi t who can either agree or d isagree wi th the ori gina l
imp ression. T his a llow for a ystem > here discrepanc ies can be
recorded and later studi ed fo r particular patterns of error.
In th e tudy by Mate e / a/., an add iti o na l communicati on tool
was impl emented a longs ide PACS, ca ll ed Co ll aborative N otificati on
System (C
), w hi ch was used in th e setting of urgent or emergent
radi o logy4 . C
con i ts of a page r notifi cati on syste m between th e
radi o logist and referri ng physic ian, and allows for image to be read
immediate ly, and the d iagnosis paged to the referrin g phy ic ian w ho
can then acknow ledge its receipt. The system was shown to improve
documentatio n, and provided an exact record of th e communicati on,
whi ch wo uld not be ava il abl e wi th per on-to-person communicati on.
CN is j u t one way in w hich PAC has been shown to fac ilitate
radi o logi t wo rkfl ow.
Additiona l bene fits of PACS include an increase in 1mage
ava ilab ility as we ll a a decrea e in time pent trave lling to the
radi ology department 5 A nother report de monstrated th at PA CS
enh a nced co mmuni ca ti o n betwee n radi o log i ts a nd re fe rrin g
ph y icia n by decrea ing e rro rs re lated to in co rrect pati e nt
identifi cati on, and increased the e ffi c iency of meetin gs by pro iding
readil y ava ilable image and report 6 . Mo re managea ble w orkflow
and increa ed effi c iency of inter-ph ys ician communi cation are
und eni able here. Unfortun ate ly fo r radi ologists, however, more
acces ibl e image data may lead to an increase in th e number of nonradi o logist ph ys ic ian w ho interpret radi o logica l studies.

SPEECH RECOGN ITION REPORTI NG
Speech Recogniti on Reportin g ( RR) has been wide ly ava ilab le in
hea lth ca re world w ide fo r the Ia t 15 or so yea r , but recentl y
Improvements have been made such that the vo ice recognition
sy.stems are more ophi sti cated, requirin g less voice-tra ining time
w 1t~ 1ncrea ed word -recognition accuracy. Radi o logi t have been a
maJor con umer o f S R~ as it ha been shown to sig nificantl y reduce
th e .tun e between examJ.nation and report fin a li za tion 7·s. Tradi ti o na ll y,
radiOl ogists wo uld di ctate report , w hi ch w ere record ed and
t~a n scribed at a .later time: and fin a ll y veri tied by the radio logi t and
s igned off for mc lus1on m th e patie nt chart or EMR. With RR
vo ic e i converted directly to tex t a fter th e RR oftwa re ha bee~
trained to th e parti cul ar user 's voi ce. T he report th en appears
unm ed1ate ly 111 th e EMR and as part of th e hospital 's PA S . The use
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of SRR along ide PA CS ha been hown to ignificantl y reduce
report completi on time a we ll a igni ficant ly inc rea e the number
of reports which are avai lable with in 24 hourss.
Another benefit of RR, how n by Bh an et a/., is th e decrease in
overall hospital operati ng costs8 The ame report, however,
publi hed data bowi ng that RR actu all y increased the amou nt of
time taken to produce indi vi dual reports, and was prone to
inaccurac ies in certai n ettin gs, for exa mpl e, when used by
practitioner for whom Engli sh was a econd lang uage. Speech
Recogniti on Reporting wa hown to have no effect on the overall
number of report produced. De pile some of it shortcomings, RR
has recently hO\ n a t improvement and wi ll undoubtedl y cont inue
to do so. It has become a main tay for many radio logi ts and other
specialties alike and ha the unique ability to be combined with
to provide a more comp lete compo ite of
ystem such a P
patient data, benefitting all member of the interdi ciplinary team.
THE FUTURE OF RADIOLOGY

ince many technologie have improved the efficiency and
accuracy of radiological reporting, there has been a parall el increase
in the adopti on of radio logical technique by other spec ialti e . Thi s i
known to many a radio logy "turf war ". The most prominent
example over the pa t 40 year are in va cular urgery and coronary
angiography. One author specu lated that the rea on for the total
ces ation of radiologi t perfom1ing these procedure was their lack
of specific knowledge in the clini ca l as pects of coronary artery
di ea e (e peciall y electrocardiology and ca rdio pharmaco logy) a
well as the ability of cardiologist to se lf- re fer 9 Palma notes that
since radiologists are not trained in the catheter lab and do not
conduct research in coronary disease, they are less adept to perform
coronary angiography. Thu s, radiologi t have largely abandoned thi
practice. One study showed that the tota l number of intravascul ar
procedure perfom1ed by radi ologist fell from 63 .6% to 49%, whi le
those perfom1ed by ca rdiolog i ts ro e from 25% to 36% from 1997
to 2002 10 . Radiologists, however, have longer and more high ly
speciali zed education that include in-depth radiati on sa fety training,
familiarity with all imaging modaliti e , and ability to detect
incidental findings " , whi ch suggests that they are better suited for
these procedures. The previous ly mentioned ph enomenon of se lfreferral has also been explored and shown to lead to an increas ing
and unnecessary utilizati on of radi ologica l se rvices by nonradiologists1 2.
The high le el of technical ability inherent in radio logy ha led
to a real or perceived weakening of the clini cal re lationship between
radiologist and pati ent. Therefore, there ha been a recent pu h
towards ol uti on termed "clini ca li sation ", wh ich reinforce the
clinical role of radiologists and their technol ogies 3·9 · 13 . Clini ca li ation
also seeks to help radiologi ts better communicate wi th other
discip lines by recommendi ng training for radiology resident in
spec ific organ patho logies, and upports the ph ys ician-pati ent
re lationsh ip by encouraging radiol ogists to maintain contact with the
patient in all phases of treatment 13. Additionall y, centers in the
Un ited States ha ve exp lored the po sibi li ty of using online im ages to
increase patient access . Thi wa found to increase pati ent
sati sfaction , and support the relation ship with and identificati on of
the radiol ogist a a profe sional responsib le for diagnosis and
treatment 14 .

or intemati onall y i po ible. 15 Telemedicine and vidoecon ferencing
wi ll also enhance large- ca le com muni cati on. The next few decade
wi ll ee further adva nces in nanotechn ology, molec ul ar imaging, and
new forms of percutaneous treatm ent. Radi ologists who have
ex perti e in electroni cs and informati c , a foundati on of specialized
clini ca l pathology and exce ll ent bed ide man ner will help shape th e
way innovation i impl emented in da y-to-day med icine.
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CONCLUSION: WILL TECHNOLOGY HELP OR HI NDER
RADIOLOGISTS?

Innovation in radio logy is influencing many as pects of medi cine
that include comm unication, management, diagnost ics and therapy.
The future of radiology undoubtedly in vo lve furt her development of
PACS and SRR systems and their becoming so widespread that
transmi ssion of images and report to pati ent mart cards, nati onally
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ne of the greate t cha ll enges in modem medi c ine is th e
ability to provide acc urate diagnosti c laboratory te t in
developing co untries and in remote areas where conve nti ona l
analytica l laboratori e are lack ing. Imag ine running a cli ni c in a
remote area o f rural Africa, the Canadian arctic, on a military fi e ld
ba e or even in a small rural community in Ontario and hav ing th e
ability to provide acc urate, rapid, po int-of-care di agnosti c lab tests
wi th out the infrastructure of a full ana lyt ica l laboratory ' There 's no
need for a cumbersome or ex pens ive mass spectromete r, a
spectrophotometer, a fl ow cytometer or even a centrifuge beca use th e
applicati on o f mi cro fluidi cs eng ineerin g to medi ca l di agno ti cs ha
enabled labo ratory tests to be performed on a ma ll microchip th e
size of a credit card that you can carry around in your pocket and
may onl y require th e use of a battery as a power so urce for analys is!
As futuri sti c as this idea seems, th e appli cati on of mi crofluidi cs
engineerin g to th e deve lopment of medical diagnostic te ts is very
much a rea li ty.

0

Mi crofluidic s eng inee rin g is a multidi c ip linary fi e ld of
eng ineerin g where th e intersecti on of th e fie ld of ph ys ics, chemi stry,
eng ineering and biotechnology have come togeth er to deve lop chips
on which the ana lys is of fluids can occur on a microsca le leve l. A
parti cular ly interestin g application of micro fluidi cs eng ineerin g
technology is th e deve lopment of a lab-on-a-chip ; a pl atform on
whi ch one or more laboratory te ts are integrated onto a sma ll chip a
few squ are centimetres in ize th at uses a very sma ll volume of fluid
for anal y is. Severa l mi cro!iters of a va ri ety of biologica l fluid
in cludin g bl ood, cerebro pinal fluid , urine, feces or sa li va ca n be
add ed to th e lab-on-a-chip fo r analys is. 1 The e chips utili ze a wide
va ri ety of techniques for analys is. The most succes fu l lab-o n-a-chip
applicati ons integrate all aspects of sa mpl e preparati on, ample
se parati on, signa l amplifi cati on and signa l detecti on on a sing le chip .
1
These chips ca n be ea ily adapted for use in remote regions since
pecialized laboratory personnel are not needed for ana ly i - yo u
simply need to appl y th e sampl e to th e chip and th e tec hno logy take
care o f the rest. In additi on to th e ir sma ll ize and portability , th e
appli cati ons of lab-on-a-chip platforms have a wide va ri ety of
adva ntages to the fi e ld of medi ci ne and are li sted in Box I (adapted
from references ( 1-3)) . A va ri ety of mo lec ul ar biology, immuno logy
and biochemi ca l techniques ha ve been adapted for use on lab-on-achip platfo rms inc ludin g protein assays, nu c leic ac id as ays, cell
sorting, and biological analyte detecti on. '.4
Since lab-o n-a-chip
techno logy has a wide variety of applications in medicine we w ill
now fo cus on two areas o f interest where we fee l the techno logy will
be rapidl y appli ed ; th e detecti on of infecti ous mi croorga ni m from
biological amples i.S· 6 and the microsca le detecti on of bi o logica l
ana lytes 7
Arguably, one of th e most important and exciting app lica tions of
th ese devices is in the ea rly and acc urate diagnosis of infecti ous
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di sease in th e developing world .1.3 5 · 6 The ability to rapidl y detect
an infecti on, a ess an infected patient 's health status and the
appli cati on of this techno logy to epidemio logica l studies in the field
are in va luab le. In order to be a useful tool in the developing world
severa l de ign challenge need to be overcome; the reagents and the
chip itself need to be stable at a wi de va riety of temperatures since
refrigerati on of the component may not a lways be feasible in the
de elop ing wo rld , th e cost of the chips needs to be low and the chips
need to have a small power ou rce for operat io n ince re liable
electri ca l infrastru cture is not found in a ll parts of the world. '·3
Re earch and deve lopment work is being undertake n to adapt lab-ona-ch ip technology for th e detection of many microorganisms from
biological amples including; HJV (reviewed in (8)), ma laria
(rev iewed in (9-1 0)), tubercu lo i 11 · 11 , di arrheal di seases 6 , pertussis 13 ,
and dengue fever. 14 One exciting lab-on-a-chip application for the
detection of enteric infection i the Di sposa ble E nterics Card (DEC)
which i able to detect the presence of Campylobacter jejuni,
Escherichia coli 0 157: H7, Shigella dy enferiae, Shiga Toxinprodu cing Escherichia coli ( TEC) and Salmonella from a amp le of
feces a ll on one microchip.6 The D EC lab-on-a-c hip techno logy
combines evera l laboratory assays to detect th e bacte ri a (see Figure
I and Figure 2 for a chematic of the chip). Bri e fl y, a ampl e of feces
i appli ed to th e chip an d bacteria from th e sa mp le are captured on
the chip by using pecific antibodie to each bacteria of interest.
The e antibodie are located in severa l different areas of th e chip.
Th e bacteria are ubseq uentl y ly ed u ing buffer and the bacterial
DNA i captured on a silica resin co nta ined within the chip. The
purifi ed bacteria l ON is ubsequently amplifi ed u ing a tandard
mo lecu lar biology technique ca ll ed the po lymera e chain reaction
( PC R) w ith ON primers spec ifi c for a gene in each bacteria l pec ies
of mterest. The end of each primer ha been de igned to contain a
flu ore cent mo lec ul e. Afte r th e amplificati o n of the bacterial 0 A
using P R, flu ore cent mo lecule are now found at th e ends of each

Figu re I. A Schemati c Di ag ram of th e Di sposa b le Enteric
(DEC) lab-on-a-c hip Techno logy.
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amplified mol ecul e of bacteri a l DNA . The next step in the process is
to detect the amplified bacterial DNA . To do thi , a laser li ght is
The fluorophore em its flu orescent li ght
directed at the ample.
which can be detected if the sample is positive for the bacteria .
Unfortunate ly, the DEC testing till require the use of a sma ll
machine for the PC R reacti on and PC R product detecti on whi ch
limits its abi lity to adapt to fi e ld conditi ons. Thi s techno logy wo uld
be useful in a sma ll ana lytica l laboratory or c linic but it u efu lne
would be limited under fi e ld conditi on .
A second appli cation of techno logy to lab-on-a-c hip capabi li ty is
the detection of ana lytes uch as e lectro lytes fro m a sma ll sa mple of
blood. The iSTAT, a device manufactured by Abbott Di agnostics,
has the capab ili ty of rapidly ana lyzing ana lytes in a few drops of
blood.7 The developers of the iSTAT have mini aturi zed e lectrodes by
depo iting electrode arrays onto sili con cartridges to create a
bi osensor. A few drops of bl ood depos ited into a sample chamber are
able to enter the caitri dge by capi llary action. Once the sample is in
the cartridge it can be treated w ith chemi ca l reagent prior to
ana lysis. At the ana lytica l stage the cartridge is inserted into a
handhe ld e lectromechanica l read-o ut device that prov ide a power
source and controls the temperature of the chip. The electrode arrays
depos ited on the s ilicon membrane can then be used to measure the
concentration of va rio us blood e lectro lytes, gases, and other ana lytes
using potentio metry (measuring the e lectri c potential),

Feces Sample
applied to sample
chamber

I':\

Antibody Capture
\,:;) of Bacteria

~

Box 1: Advantages oflab-on-a-chip technology
•
•
•
•
•
•
•
•
•
•
•
•

Small size (credit card or smaller), portability
s mall sample volumes, less invasive
rapid analysis, short processing times
low cost
no need for highly trained laboratory technicians
to perform the test
may run using a battery for power (no need for
electrica l infrastructure)
reduced reagent consumption due to small volumes
high reproducibility
reduced exposure to hazardous materials or
infectious agents due to small volumes
minimal risk of sam ple contamination
convenient disposal
elimination of human error (you add the sample
to the chip and the chip takes care of the rest)

Adapted from references (1-3} .
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Bacterial Cell Lysis
and DNA Purification

~

DNA is Eluted from Resin
and enters PCR Amplification
Chamber
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A Bacterial Gene is Ampl ified by PCR using
\,:;,) Primers Linkedto a Fluorescent Molecule

0

~
Amplified Fluorescent Bacterial DNA

•

•

I'::\

,, ,,,,.

Laser Used to Detect
\::;) Amplified DNA

-/,

Figure 2. Biochemi cal steps of the anal ysis in the chip. (A) Feces sample is appli ed to the chip and enters the sampl e well. Various types
of bacteria in the sample are represented by different ova ls. Different surface prote in s on each type of bacteria are denoted by rectang les
and tri ang les. (B) Antibodies speci fie to surface prote ins o n the bacteria of inte rest capture the bacteri a in the chip. Thi s exampl e shows
bl ack coloured bacteria captured in the upper chamber a nd grey coloured bacte ria in the lower chamber. Bacteria whose surface prote ins
are not bound by the antibodies are washed away. (C) Captured bacteri al ce ll s are lysed in bu ffe r and bacterial DNA is purified on sili ca
resin . (D) Purified bacteria l DNA is e luted from the res in and enter the PC R amplifi cati on chamber. (E) A bacteria l gene of interest is
amp lifi ed using a standard mol ecul ar biology technique ca lled PCR. Sma ll DNA mo lecules (primers) specifi c for the gene of interest are
found in thi s chamber. Primers are denoted as arrows in the di agram and are linked to a fluoroph ore (a flu o rescent mo lecule) denoted by a
star. (F) The ge ne of interest is amp li fi ed exponentia ll y (there are many copies) and now conta ins flu orophores on each end. (G) Amp li tied
bacterial DNA fluoresces when laser li ght is shone on the sampl e giving a readout, thus, leading to the di agnosis of the infecti o n.
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amperometry (measuring the fl ow of an electri ca l current) or
conductimetry (mea uring the conductance) of the sample. 7 These
values are then di spl ayed on a screen. Different chips are u ed for
different analyti ca l application and each chip is dispo ed of after
one use. All the chips use the sa me handheld electromechanical
read-out device.
We have only focused on two application of lab-on-a-chip
technology; however, there are numerous u e for this technology
and many approaches to the miniaturi zation of biochemi ca l,
molecular biology and chemical a ays for u e on microchip . The
miniaturization of medical technologie may very well revolutionize
the deli very of medical care in the near future. I your pocket ready
for the lab-on-a-chip?
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hysicians are often limited by techno logy in the ir pursuit of
patient we llbe ing. Take fo r exampl e a pati ent sufferin g from
stroke among a myri ad of other d iseases. Having the capac ity
to measure blood flow to va rio us organs and to specifi c regions
within those organs - vita l for proper bodi ly fun ctions - can have
prodigious impli cations o n dec iding w hich treatment pl an to fo llow.
Fortunately, measuring fun cti ona l bodi ly processes with respect to
hemodynami cs has been a specia lty of Dr. Ting-Yim Lee. Dr. Lee 's
research on blood fl ow has contributed substantiall y in
allowing physicians to apprec iate a more comprehensive
picture of some of the most severe di seases. But the journey
there has not been easy.

P

Winston Churchill once
sa id, "Continuous effort is
the key to unlocking our
potenti a l. " Thi quotati on
best exemplifi es the dri ving
fo rce behind Dr. Ting-Yim
Lee's research endeavours.
Having grow n up in Hong
Kong, Dr. Lee travell ed to
Lo nd o n U ni ve r s i ty in
England to pursue graduate
degrees in Radiati on Physics
i n th e D e p a rtm e n t of
N u c lea r M e di c in e . To
furth er hi s research interests,
he immigrated to Canada in 1983 . Dr. Lee exemplifi es the
qualiti es of a committed, ambiti ous scientist who manages to
go above and beyond the typ ica l protoco l. He is hard wo rkin g,
humbl e and extreme ly kn ow ledgea bl e in hi s research deri ving
fun ctional and physio logical info rmati on from contrast CT
images. The Uni versity of Western O nta ri o has been fo rtunate
enough to have him fo r well over two decades now. Whil e at
Western, Dr. Lee quickl y emerged as a leader by deve loping a
renowned fun ctional CT Imaging program. Hi s as pirati o ns are
to study fun cti ona l processes in the human body us ing CT
imaging, spec ifi cally those w ith respect to hemodynami cs. Hi s
hallmark is in pi oneerin g a method of using x- ray dye and CT
scanning to measure bl ood fl ow. Thi s intri cate research is
making substantial contributi ons to severa l di seases including
stroke, cancer and ca rdiac di sease.
In stroke, clots or injury to bl ood vesse ls can prevent
proper delivery of oxygen and substrates (ma inl y g lucose) to
the brain. The standard treatment is thrombo lysis. However,
thi s must be done in a narrow time frame to meet current
treatment criteri a. Dr. Lee is develo ping too ls to improve the
time li mitation cri teria fo r treatment . He has developed

so ftw are, whi ch can measure fu nctional as pects of bl ood fl ow to the
bra in (see Fi g ures I ,2) , in c ludin g ri s k fo r he m o rrh ag ic
tran sfo rmati on. Takin g into acco unt ischemi c brain changes after a
stroke can lead to more inclusive treatment criteria for thrombo lysis.
As such, thi s could lead to reduced di sabili ty fo ll owing stroke,
therefore poss ibl y miti gating other severe treatment co mpli catio ns.

Fig ure I - Patient # I (A) admi ss ion non-contrast CT image, ( B) cerebral
bl ood fl ow map (sca le 0- 150 m l/mi n/ 1OOg), (C) cerebra l blood vo lume map
(sca le 0-8 ml/ 1OOg) obta ined 7 hours after stroke onset. initia l CT
hypode nsity corres ponds to area of reduced C BF and CBV (solid arrow)
whil e the dashed area shows an area of decreased CBF w ith normal/e levated
C BV. Without recana lizati on, entire ischemi c area at admi ss ion (CBF =
16.48, CBV = 1. 8 1) progressed to infa rcti on on the day 5 non-contrast CT
(D). Subtle stripes of isodensity surro unded by the low density of in fa rcti o n
are typi cal fo r petechiae in cortex. Patient #2 (E) Admi ss ion non-contrast
CT image, (F) cerebra l blood fl ow map (sca le 0-1 50 ml/mi n/ 1OOg), (G)
cerebra l blood vo lume map (sca le 0-8 m l/ 1OOg) obtained 157 minutes after
stroke onset. Large ischemi c area on th e admi ssion C BF (das hed arrows) w ith
an area of severe ly reduced C BV in the deep grey matter (so lid arrow).
Spontaneous recana lizatio n occurred pri or to the 24 hour fo llow-up CTA.
(H) 5-day NCCT co nfinns infarct in the deep grey matter (matched decrease
in CBF and CBV at admi ss ion) w ith progression of some surrounding ti ssue
to in fa rcti on. A large porti on of the mi smatch area at admi ss ion (decreased
CBF, nonna l/e levated CBV) recovered and did not show in fa rctio n on the 5day no n-contra t CT. lsodense region central w ithin the low density
infa rcti on is typical for a hemorrhagic region.
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to 7000 copies are curre ntly in use, ~ ot onl y in orth ~merica: but
· As ia , Europe and Australi a. He also has mternat10nal
aI o m
·
f
coll aborations as a resul t of hi ex perti se i_n CT perfuston . 0 ne o
these is with the Ameri ca n Co ll ege of RadiOlogy lmagmg Network
(AC RIN), an organizati on funded by the National Ca n~er Institute
(US). One of hi main research commitments was pushmg through
an appli cation of imaging biomarkers m cancer m a n ageme~t, lookm_g
at treatment efficacy, treatment response, and earl y detectiOn . H~ ts
now in vo lved with a trial u ing CT perfusion to look ~t ovana_n
cancer, which will hopefully be approved as the_ first maJor multicentre tri al of its kind with over 20 ites in the Umted States. Dr. Lee
al 0 con tantly ha in fo rrnal co ll aborations ?ccurring, fr~m working
with Ita lian re earchers on analysi of thetr stroke pattent data to
getti ng hi oftware into hospi tals in China, tho u~h he co ~ fesse ,~hat
that i go ing slowly. " Havi ng the right contacts ts very dtfficult, he
admits. " It seems a though it's till not onl y what you know, but al so
whom you know."

Figure 2. Pati ent #3. (A) Cerebral blood fl ow (C BF ) map hows
evere decrea e in bl ood fl ow in left MCA territory. (B) Cerebral
blood vo lume (C BV) map hows similar severe decrease in bl ood
vo lume a blood fl ow in the same left MCA territory. The concurrent
decrea e in CBF and CBV sugge t that the tissue in the left MCA
territory was already infracted with di rupted blood-brain barrier
(BBB ) as shown by the increase in BBB pern1eability in (C). This
pati ent went on to develop hemorrhage in the left MCA territory as
hown by the ' light haze' in the region in the non-contrast CT scan
(D) acquired 5 day later
In many type of cancer, hypoxic tumours are resi tant to
treatment. Furthermore, they may undergo genetic alterati on
re ulting in increa ed res istance to treatm ent, rapid proliferati on and
advancement to metastasis. Dr. Lee' resea rch undertaking i to
des ign a new methodology of imaging tumour hypox ia using P T/
CT cans as an alternative to bi op y or urgery. If successfull y
validated, Dr. Lee's resea rch ca n Iran late to ph ysicians specifi ca ll y
targeting hypox ic area witll higher do e of radi ation and/o r u ing
drugs to enhance the effect of radi ati on in order to achi eve a cure.
Si milarl y, T can of hypox ic tumour can help ph y ician monitor
effecti veness of treatment. Also, hypox ic imaging of tumours can be
used to defin e selecti on criteria for pati ents that may benefit from
genetic therapy.
Whil e Dr. Lee deli ver superi or results at the laboratory leve l,
he does admit to facing chall enges in translating research from the
bench to th e pati ent bedside. There i always the confli ct between
what is best for research and what is practi cal in a clini ca l
environment. A good exa mpl e is how to use CT scanners in the
hospital optimall y for resea rch. He has to des ign imaging protoco ls
that will acquire the necessary data but more importantly are
acceptabl e to pati ents and does not slow dow n the workflow of a
bu y T scanner. After all , T scanners are the workhor es of
modern imaging department ; the demand for their use is far greater
than the time ava il abl e.

Fi nally and particul arl y, the golden questi on: h o:V . does he
manage to do it all? Dr. Lee didn 't try to sugar coat tt: tt ts always
very tressfu l, and everyone who wants to do well in hi s or her
profes ion \ ill have this kind of tress. In the past, ht s strategy wa
to th ink: "If onl y I could get through thi one cri i , I will be happy."
Unfortu nately, he woul d have one crisis after another, and thi s
became a prob lem. Recently he ha come to the rea lization that
" Happiness i a journey, not a destination." Thi s statement, which he
now ha taped to the wa ll in fro nt of hi s de k, wa a wakeup ca ll for
him . He reali zed that he could not constantl y li ve fro m one crisis
moment to the next. "You can' t rea lly do thi s for long without
burning out. You have to enj oy each step of the journey whil e you ' re
trying to get to your de tination. Fortunately, being a scienti st or a
clinician, you can have thi luxury." He now approache each day not
onl y a a new probl em, but a new learning experience, never hav ing
to repeat what he had to do before. He reli hes hi s "Aha!" moments tho e that he can refl ect on to remind him ofl earning omething new.
Havi ng th i mind et allow him to enjoy hi s journey every tep of the
way, not j ust at the end .
ltimately, what doe he want in the end? " I just want to
tran late what i goi ng on with my pencil and paper and animal
re earch. It ' nice if ometh ing comes out of all the pipe dreams you
have, ifyour methodol gy i adopted the world o er. If you can ee
that the impact of \ hat you' re doing means omething in a clinical
en e." Dr. Lee chuck led a he bared that ometime he find s he'
not even acknO\ !edged in paper when hi s softwa re i being used.
" But I can't complai n becau e the product ha been commercialized
and th i j u t mean peop le are u ing it. When what you ha e toiled
fo r bea r fruit, if it is a tuall y helping patient , it make it ea ier to
enjoy the journey." Dr. Lee al o has the quotation "Genius i onl y [a
great capaci ty fo r] great patience" by Georges-Loui Leclere Buffon
di pl ayed on hi de k. He ex plained that he was "a pl odder, a late
deve loper." ccording to him , he wa never someone who wa a tar
upon graduating from hi PhD program. Jokin gly, he uggests that
thi BurTon quotati on is something to remember in keeping yourse lf
out f depre ion. But it i al o important to keep in mind:
per everance rea ll y matters. That is something to keep in mind a we
stri ve to achieve happines during our own journeys.

There is no doubt that the fun cti onal CT imaging software has
had an internati onal impact. Since GE Hea lth ca re has li censed it, it
has been di tributed all over th e world . At Dr. Lee's last count, clo e
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A

50 yea r o ld ma le pre ents to the c linic w ith a hi story o f feve r

and cough lasting a wee k. He has recentl y immi grated to
Canada, and ca nnot co mmuni cate we ll . Upon exa minati on,
he is found to be hypotens ive w ith an e levated heart rate. A chest xray is ordered, and it indi cates pu lmonary infiltrates. Thi s findin g,
along with the clin ical presentati on, suggests that the pati ent has
communi ty-acquired pneumonia. He needs treatment, but w hat is the
infection that brought about thi s epi sode? What sho uld the clini cian
do when there is a limited amount of time to find the pathogen?

It is establi shed that timely admini strati on of antimi crobi a l
therapy i criti ca l for good pati ent outcome.l.2· 3 Unl ess the c lini ca l
features and hi story are very suggesti ve o f a particul ar causati ve
agent, the therapy must be empiric. The recommendations in thi s
case are to begin with broad-spectmm antibioti c therapy, and to
adjust the treatment regimen o nce laboratory cultures identify the
best antibiotics to use .2 Thi s approach, a lthough logical g ive n the
current potential of identi fy ing the causati ve age nt, is fraught wi th
problems. For one, inappropri ate initi a l empi ric therapy is an
independent ri sk factor for increased patient morta li ty and durati on
of hospitalization.4 Furtherm ore, the use o f a vari ety of antibioti cs
may promote the deve lopment of antibi oti c resistance amo ng
pathogenic orga ni sms. Idea ll y, once the c lini ca l picture is suggesti ve
of an infectious cri sis, rapid identificati on o f the causati ve agent
would a llow fo r targeted therapy that optimizes outcome w hile
minimizing the ri sk fo r the deve lopment of antibi oti c resistance.2
While current medi ca l techno logy does not have th e rapid
identification capacity in a ll cases of infecti o ns, it is progress ing
steadil y towards thi s goa l with the applicati o n o f mo lecular geneti cs
in the clinica l environment.
GENOTYP l NG
The di stinguishing characteri sti c of every organ ism must li e in
its genes. Two pathogenic bacteri al o rga ni sms may appea r a like in
presenting clinica l symptoms, on gram sta in , and in the ir growth
characteri stics, yet be di stinctl y di ffe rent and require di ffe rent
treatment. The differences betwee n these organi sms that cannot be
seen based on culturing and stai ning a lo ne w ill be re fl ected in the ir
geneti c make-up . Gene sequenc ing, there fore, is an excell ent
approach for the identifi cati on of a parti cular infectio us orga ni sm
from a slew of poss ibi liti es .5 As sequenc ing techno logy becomes
more e ffi cient, the approach will not onl y be hi ghl y sensiti ve and
specifi c, it w ill be rapid and inexpensive. Befo re thi s can happen,
however, hurdles must be overcome. One i specific ity - there must
be an identi fy ing geneti c seque nce for every path ogenic o rga ni sm.
Thi s is no easy task g ive n the large va ri ety of known pathogeni c
species as we ll as newly evo lving o nes . But the a uto matio n of ge ne
sequencing coupled with co mputer process ing power a llows for the
a lignment of who le genomes fro m di ffe rent pathogeni c spec ies in
order to identi fy key differences that can be u ed to di sting ui h one

in fection from another. 6 As these geneti c d iffe rences are ide nti fied, it
rema in s for highl y sensiti ve tools to be developed that ca n assay fo r
the di ffe rences in clini ca l specimens.
Let us return to the pati ent w ith pneumonia symptoms. He i
recentl y immi grated, meaning the infec ti on could have been picked
up at hi s pl ace of ori g in . One of the most common g loba l human
in fec ti ons is w ith members of the fa mily Mycobacteriaceae.7•8 They
ca n be mi ssed as causes o f communi ty-acquired pneumoni a because
o f the absence o f readi ly ava ilabl e rapid di agnosti c tests.9 Recent
techno logica l adva nces have made progress in recti fy ing thi s
probl em. In identi fy ing a myco bacteri a l causati ve age nt, it would be
important to di stin g ui sh tubercul ous mycobacteri a from no ntu berculous myco bacteri a (NTM ) 8 · 1 Furthermore, it wo uld be
impo rtant to determine the parti cular subspec ies as this can be critical
in identi fy ing the source of the infecti on 8 Takin g adva ntage of
kn ow n genomic data for the myco bacteri al orga ni sms, multipl ex
PC R is one assay that can be used.

°

MULTI PLEX PC R
The princ iple o f the po lymerase chain reactio n (PC R) is to
specifica ll y amp li fy a target DNA sequence using thennostab le
enzymes such as Taq po lymerase or Pfu . 11 The sequence to be
amplifi ed is loca lized between two DNA primers that hybridi ze to the
target DNA. The maj or adva ntage of thi s technique in clinical
di agnosi is that it requires very littl e startin g mate ri a l for
amplifi cati on. 12 For in fec tions w ith mycobacteri a, thi s could allow
for identifi cati on without the culturing step that i so timeconsuming.13 Unlike traditi onal PC R techniques whereby a sing le
target sequence is amplifi ed, mu ltiplex PC R is able to specifica ll y
a mpli fy severa l target sequences in o ne reacti on.8· 14 Thi s poses
severa l technica l cha llenges because every sequence in the reactio n
requires an optima l temperature and buffer for amplification i 4
Furthermore, once the reaction conditi ons are optimized it is
necessa ry to di sting ui sh one amplified sequence from another. Whe n
these cha llenges are overcome, it is possibl e to ampli fy severa l
species-specific ge neti c sequences, including testing fo r the presence
of a ntibi oti c-res i tance genes. 15.16,17
In the case o f mycobacteria l infectio ns, mul tipl ex PC R can
di tingui sh between M tuberculosis complex (MTC) and NTM based
on kn own ge netic differences. 1 ·19 These have been tested on clini cal
spec imens, yie lding hi gh sensiti vity and specifi c ity.B. I9.l0,21 Other
multiplex PC R assays ex ist that can di stingui sh between the TM
ub pec ie , in partic ul ar those of the Mycobacterium avium compl ex .
8 The maj or adva ntage of a ll of these assays is the sensiti vity and
rapidity of PC R, a ll ow ing for very sma ll amounts of DNA sequences
to be detected w ithin severa l ho urs. 12 However, res ults must be
interpreted w ith caution, as the poss ibility of fa lse negati ves is
con ide rabl e w hen runn ing severa l PC R amplifi cati on reactions at
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once 14 In additi on PCR may be prone to fa lse positi ve results since
very .minute amou~ts of DNA may be amplified considerabl y. 12· 14 •21
SPOLIGOTYPI NG

Whereas multiplex PCR has found a use in di stinguishing. MTC from
NTM and identifying subspecies of the NTM group, spoli gotypmg IS
a method that has been deve loped and used to identi fy and genotype
strains of bacteri a in the MTC group 22 •23 The method is ba ed on the
presence of conserved direct repeat (DR) sequences separated by
non-repeating spacer regions in the genomes of these bactena.
Di ffe rent strain vary in the number of such DRs as well as the
length and sequence of the space r regions 22 By des igning
oligonucleotide primers that hybridi ze to conserved regions within
the DRs, it is poss ibl e to run a PCR reacti on that yield a large
variety of amplified D A sequence of different sizes (Figure IA) .
The pattern of the e amplified D
sequences is characteristi c of a
strain of MTC bacterium (Figure I B)22

restnct 1on fragment length pol ymorphi sm (RFLP) a?alysis. 26 The
latter method is based on the digestion of mycobatenal DNA With
endonucleases, and the reso luti on of species-spec ific fragments by
compari on of their migrati on patterns on a geJ.2 8
rtPCR is a technique that allows for the rapid, quantitative
amplifi cati on of DNA using PCR. As the P.CR reaction is run, the
PCR product generated during each cycle IS bound by a dye that
flu oresces at a particular wave length when ~ound to double-stranded
DNA. The resulting flu orescence is quantified dunng each cycle,
yielding a rea l-time DNA amplifi cati on. curve . 12 The amplification
product is then subjecte? to HRM analys is, whereby a .known am ~~ ~!
of D A i melted by ra1 mg the temperature m fi xed mcreme~ts . ·
Since the melting temperature (Tm) of double-stranded D A IS very
ensiti ve to equence 29, a ignifi cant difference in Tm may be
ob erved between Beiji ng and non-Beijing trains of Mycobacterium
by virtue of a ingle
P.
rt PCR wi th HRM analy i wa appl ied to clinical specimens and
B

A

...

..

Figure 1. The bas ic principles invo lved in spoli gotyping. A Two juxtaposed blue rectangle indi cate a conserved direct repeat (DR) in the
genome of a parti cul ar strain of Mycobacterium tuberculosis compl ex . Onl y a ubset of DRs are shown fo r clarity, whereas there would be many
more in the actual organi m. PCR primers are des igned to hybridize at particular locations within the DR a shown by the arrows. An arrow
pointing to the ri ght i a forward primer, whil e one pointing to the left i a rever e primer. The primers may hybridi ze at any of the DRs, and the
resulting pos ibl e PCR products are indicated. The red square indicates a specifi c equence in the fir t pacer region, whil e the yellow rectangle
indi cate a pecifi c equence in the econd space r region.
B The PCR products fro m A are hybridized to an array containing immobili zed
oli gonucleotides whose sequences COITespond to a spacer region. Examples of thi arc demon trated with the red square and yellow rectangle
from A, whereby the equence in each of the co loured rectangle is recogni zed by a spe ific oligonucleotide probe on the array. Hybridizati on
between a PCR product and the array is ind icated by a bl ack circle on the spoli gotype. Each row on the array corre pond to hybridizati on
signals from a single train .
poli gotyping has been appli ed to clini ca l spec imens23 •24 It is a
rapid a ay becau e it relie on PCR, and studies have shown that it
is sensiti ve and speci fi c to MTC infections. 22 ·23 It has the additi onal
advantage of bei ng abl e to di tingui h train s of M. bovis fro m those
of M. tuberculosis, a di ffi cult task with traditi onal techniques 22
Much of the u e of poligotyping has in vo lved contact tracing in
instances of u pected MTC infecti ons so a to limit the spread of
infec ti on.22 •25 Fu rth er studi es are und ergo in g to definiti ve ly
determine its use in clini ca l di agnos is and genotyping of MTC
infecti ons.
REAL-TIME PCR (rtPCR) WITH
MELTING ANALYS I S (HRM)

HI GH-RESOLUTION

A spoligotype performed on clini ca l isolates from the pneumoni a
pati ent revea led a pallern co nsistent with a hi ghly virul ent spec ies of
Mycobacterium belonging to the Beijing lineage. 26 Thi s lineage is
known to be hi ghl y tran mi ss ibl e and often drug-res i tant, requiring
spec ifi c treatment reg imens that differ from other mycobacteri al
infecti ons 27 For th e purpo es of rapidl y confinning an infecti on with
thi s pathogen, one a say that can be used is rtPCR with HRM
analysis. Thi assay reli es on the presence of a single-nucleotide
polymorphi m ( NP) corresponding pec ifi ca ll y to the Beijin g
lineage that was identi li ed u ing methods such as spoli gotyping and

30

re ulted in nearl y 100°o ensiti vity and spec ificity as long a there
was a uffi cient load of bacterial orga ni sm in the sputum .2 6 It ha the
additi onal ad antage of being very rapid and relati ve ly inex pensive
to perform .29 When clin ica l iso lates from the patient with pneumoni a
ymptoms were subjected to the a ay, the pre ence of the Beijing
lineage of M. tuberculosi was confirmed.
CONCLU ION

The assays menti oned here in the context of a poss ible infecti on with
a member o f th e famil y Mycobacteriaceae are intended to
demon trate the utility of the gene sequence in rapid clinical
di agno i . Improvements in the effi ciency of gene sequencing a well
as bioinformatics analys i are generating a large amount of data
rega rding pecifi e geneti c target for each pathogenic organi sm that
could be as ayed by techn iques based on PCR. Some of these
technique , including multip lex PCR, spoligotyping, and rtPC R with
H RM demonstrate that assays can be des igned and implemented in a
clini ca l setting to identi fy parti cular infectious organi sms. A the e
as ays become less ex pensive and standard in all microbiological
laboratori e , their rapidity will all ow for the u e of appropriate
targeted therapy in order to optimize patient health whi le minimizing
the nsk of th e development o f antibi otic res i tance.
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The application of three dimensional laser
surface scanning and imaging in a case of total
nasal reconstruction
Michal Brichacek (Meds 2013)
Faculty Reviewer: Dr. Douglas C. Ross, MD MEd FRCSC (Department of Plastic Surgery)

he earli est reports of reconstru cti ve surgery are presented in an
ancient Egyptian medi ca l text datin g back to 1600 B.C. th at
describes the treatment of nose, ear, lip, and chin injuri es . 1
However, it was Indi an surgeons who are credited with empl oyi ng
the first de finiti ve plasti c surgery techniques, w ith spec ifi c report
describin g Sushruta performin g th e fir t rhinopl asty in 500 B.C .2

T

Pl asti c surgery developed at a time when th ere was a
tremendous need for reconstru cti ve correcti on o f catastrophi c
deformities : after World War 1_3 Never before had surgeo ns been
presented w ith such extensive injuri es that required compl ex and
innovati ve reconstructi ve procedure . The Greek work plastikos,
meanin g to be capable of bei ng molded, wou ld become used to
describe a fi eld where surgeo ns molded th o e devastated by th e
injurie of wa r4
As technologica l adva nce have improved protecti ve gea r and
medi cal advances have improved adva nced trauma care, th e
proportion of soldi ers dy ing in combat a a result of thei r injuri es has
markedl y decreased . Soldiers are currentl y survi ving injuries th at
wo uld have kill ed them in any prev ious conflict, but as a res ult th ey
are survi ving with mass ive facia l and crani a l injuri es th at require
compl ex reconstru cti on.

PATIENT PRESENTATION

flap would still be intact, whi ch means th ere was a significant chance
of it fai ling and becoming necroti c.
Despite th ese risk , the patient fe lt very strong ly opposed to a
nasa l prosthesis and exp resses hi desire for surg ica l reconstruction .
Bei ng awa re of the igni ficant ri k of com plicati ons and the need for
multiple stage , th e patient elected to proceed with urg ica l
reconstruction.

TECHNOLOCICALPLA

The no e is a complex three-dimen ional obj ect that must be in
harm ony wi th the rema inder of the face . The cha ll enge with thi s case
was to create a new nose from nothin g. In extensive facial soft tissue
injures th e surgeo n can use the remnants of th e nose as a guide in
ord er to create a new nose. In thi s case, even th e cartil age, which
serves as a framewo rk fo r the no e and co uld act a a guide, was
absent.
It was deci ded that technology could he lp with thi problem by
providing th e s urgeo n with two types of guides to a id him in the
reconstru cti on: a two-d imen iona l template showing the complex
area of kin that must be taken a a fl ap from the forehead, and a
three-dimensional plastic mo ld bowing the fin a l shape that th e
surgeo n should tri ve to achi eve during the creati o n o f the ubsurface
framework of th e nose.

M.F. is a 2 1-yea r- old African American wa r veteran who sustained
signifi cant facia l and body trauma in Iraq. He was
in vo lved in a situation where a ve hi cle ex ploded and
he ultimate ly rece ived multipl e oft ti sue injuries
and facia l fractures . This resulted in amputati on of
hi s left arm and left him with an ex treme ly fl attened
nose. He presented to John s Hopkins Ho pita!
seek ing nasal reconstru ction.
Nasa l reco ns tru cti o n wo uld have to be
perform ed through a midline forehead flap, where a
large fl ap o f skin is taken from th e middl e of th e
forehead, rotated, and fold ed dow n to create a new
nose.5 Due to th e lack of underl y ing ca rtilage to
prov ide support for th e nose, rib ca rtil age wo uld
have to be harvested and a nasa l subsurface wo uld
have to be recreated. Additiona ll y, a radi al forearm
free ti ss ue transfer would need to be perform ed to
provide a vasc ulari zed interna l skin lining for the
di sta l half of th e nose.
However, the patient was informed th at he was
not a good candidate for thi s procedure du e to the
need for multip le stages and hi s elevated ri sk for
failure . Due to hi s signifi ca nt fac ial oft ti ss ue
injuri es, it is unlikely th at th e bl ood suppl y to thi s
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Figure I. Three-dimen sional laser
scannin g is used to create a di g ital
model of th e pati ent's face in the
orig ina l conditi o n.
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The Art as App li e d to M edicin e
di vision at Johns Hopkins bega n by taking a
plaster mo ld of th e ex istin g condition of the
patient' face. U ing thi s and photographs
prov ided by the patient 's fa mily, a wax
model wa created of the patient ' nose
be fore hi s injury. This wax mode l wa th en
ca t in pi a ter and sent to Direct Dimen ions
Inc. (Owings Mill s, Maryland) for surface
scannin g and digital manipu lation of the
re ulting 3-dimensiona l mode l.
The mold is scanned usi ng a laser
urface scanner (Perceptron Laser Scanning
Sy tems, P lymouth, Michigan) that creates a
three-dimen sional point c loud of data that i
converted into a resulting three-dimen ional
computer model usin g Poly Works oftware
(lnovmetric Software Inc, Quebec City,
Quebec, anada). In the same manner, th e
patient ' injured face was th en Ia er smface
canned and created into a three-dimens iona l
computer model (Figure 1).

DI SC lJ SS I0 N

Figure 2. A th ree-di mensio na l tra nslucent
plastic mode l served as a guide for the nasa l
tructure du rin g the procedure, while the
two-dimensional shaped served as a gu ide fo r
harvesting of the fl ap fro m the fo rehead.
The three-dimensiona l mode l of the pre-mj ury nose wa then
superimpo ed into the proper pos itio n o n the patient 's inj ured face,
show in g a three- dim e ns io na l re nditi o n of w ha t th e id ea l
reconstruction would achi eve. F rom thi s combined mode l engineers
were able to determine the dimensions of a three-dimensiona l mode l
molded in clear plastic to be used as a surg ica l guide, a nd usi ng
complex mathematica l si mulatio ns engi neers were abl e to unro ll the
complex shape of the three-d imensiona l pre- inj ury nose onto a fla t
two-dimensional surface. (Figure 2) Th is served as a guide to the
surgeon du ring the procedure for both the shape and size of the fl ap
of tissue to be harvested from the forehead.
Ultimately, the patient req uired six separate procedu res to
complete hi s reconstruction. Hi s recovery was complicated by an
MRSA infec tion as well as a sma ll degree of d ista l fl ap necrosis.
Fortunately, total fl ap necrosis did not occur and the rema inder of the
flap was salvaged. The patient was extreme ly pleased w ith the result
and was extremely satisfied that he was abl e to have both the fo m1
and func tion of hi s nose restored (F igure 3).

More recent ly, the implementation of threedimensional object canning and vi sualization ha
been applied in the medical field to provide great
benefit to both surgeons and patients a like. By
app lyin g this techn o logy, a rad iation shi e ld was
created to protect adjace nt tissues in the treatment
of head and neck cancers.6 The creation of threedime ns iona l breast mode ls through imaging has
become possib le in order to he lp guide surgica l
manageme n t 7 In more of a mai nst rea m
applicati on, surgeo n ca n show patients expected
res ul ts after s urge ry in a dy na mi c th reed imensiona l view usi ng imaging systems such as
the Canfie ld Vectra M3 (Canfie ld Scientific Inc,
Fa irfie ld, ew Jer ey) or the Ax is T hree XS200
(Ax is T hree Inc, Boston , Massachusetts) .

T he patient in thi s case presented with an
extreme ly cha ll eng ing defect due to a co mbinati on
of signi fica nt facia l soft tissue tra uma, multi ple
facia l fractures, as well as the absence any
ubsurface nasa l fra mework. Ca es of total or subtota l nasa l
reconstructi on are particu larl y cha llengingly as the reconstructed
structure must be vasc ular in order to hea l predictably, stable in order
to with stand the scar contracture and maintain symmetry, yet at the
a me time be fu nctio nal enough to be acceptab le to the pati ent 's
li festy le. 8

T he construction of an abstract th ree-d imensiona l obj ect such a
the nose from a fl at segment of ti ss ue is extremely di ffic ult in the
absence of a subsurface fra mework. By using novel techno logical
inn ovations invo lving three-dimensio na l laser surface scanning and
imaging, the li ke lihood of achi eving a favo rable resul t is potenti all y
increased. The creati on of a custom made translucent template fo r
use durin g the procedure is achieved by the combined efforts of the
patient, the anaplasto logist, and the surgeo n.8 The templ ate is created
such that it anti cipates the thi ckn ess of the skin that w ill be provided
by the fo rehead fl ap and serves as a surgica l guide for the surgeon in
the c reatio n of the subsurface framework of the nose.
T he applicati on of three-dimensional lase r surface scatming and
mode ling is a powerful tool that can be utili zed in order to aid in the
visua li zati on of c ha ll eng in g defect as he lp in th e surgica l
reconstructi on of the e defects. A lthough still in its in fa ncy, as thi s
tec hno logy evo lves and its fu ll potentia l becomes rea li zed, it w ill
ure ly fi nd many more ap pl ications in medic ine and particul arl y in
the fie ld of reconstructive plasti c surgery.
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Candles to computers: the story of minimally
invasive procedures
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Faculty Reviewer: Dr. Terry Peters, PhD (Department of Medical Imaging, Medical Biophysics, and Biomed ica l
Engineering)

or many peopl e, the words "min imall y in vas ive surgery"
conjure up vision of medica l ro bots, MRJ machines and
nanotechnology. Although we frequentl y herald minimall y
invasive procedures as the fu ture of surgery, the concept is much
older than most of the technology it is associated with . It is an
ancient vision enabl ed by many tec hn olog ica l deve lopm ents
unrelated to medicine - the introduction of electric ity, digital video,
video game graphics, and industri al robots have all pl ayed major
roles in shaping the way surgery is practi ce today.

F

John D. Fi sher ( 1798 - 1850), and Antonin J. Desormeaux ( 18 15 1894). Desorn1eaux was the fi r t to use an endoscopic instrument for
therapeuti c purposes when he used his endo cope to remove a
papilloma from the urethra.4 Eventuall y, it was reali zed that "to light
up a room one mu t carry the lamp inside2, and the idea of the
endoscope it elf as a Iight source was born .

WORKlNG IN THE DARK

The first documented attempt to "look inside" the internal organs was
described by Hippocrates (460-375 BCE) in a pa sage referring to a
rectal speculum (Figure I ). 1 Roman medicine also describes simil ar
instruments, including a three-bladed vaginal peculum from the
ruin of Pompeii .3 The initial attempts to make a di agnos is by
examin ing internal body orifi ces all faced the sa me probl em:
inadequate lighting. Almost all of the earl y too l were designed to
max imize the amount of external ambient li ght avail abl e for direct
visuali zati on of internal structures.

Figure 2. Construction drawing of the " Bozzini scher Lichtleiter".
Image courte y of the Medica l Univer ity of Vienna, Department of
Hi tory of Medi cine .

Figure 1. xampl e of a rectal speculum simil ar to the one described
by Hippocrates. Image courtesy of the Hi storica l Co llecti ons &
Servi ces of the Hea lth Science Li brary, Uni versity of Virgini a.
The first attempt to design a tool pecifi ca ll y guiding li ght to the
target was an instrument call ed the " Li chtl eiter" des igned in 1806 by
Phillip Bozzini ( 1773 -1 809), a young obstetrician (Fi gure 2). Thi s
device was an elongated thin funnel that could be passed into an
orifi ce. The end of thi s dev ice wa a stand carrying a candl e for
lighting. Re fl ectors directed candl elight down the funn el. Many
funn el of different sizes could be u ed, and it co uld help examine
the bladder, rectum , vagina and naso pharynx. Although Bozzini is
now. credited with creating th e first endoscope, the dev ice was poorl y
received. The candl e produced heat and smoke leading to burns, the
device co uld be painful to introduce, and lighting was stil l
inadequate. 2•3 In the foll ow ing years, attempts were made to improve
the des ign by many peopl e in cluding Pierre ega las (1 792 - 1874),
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. With the invention of the incande cent light bulb by Thomas
d1 son ( 1847- 1.9.3 1), endoscopy bega n to be taken more eriously by
med1 ca l practiti oner . Th ere were imultaneo us deve lopments
~ystosco py, thoracoscopy, and gastroscopy. Many modificati on and
~mprove m e nt s were made to endo cope des igns in the 20'h century,
1ncludmg the u e .of insuffl ati on by Georg Kelling, and the
deve lopment of fl ex ible fibre-opti c in truments pi oneered by Bas il
Hirschow itz ( 1925)5
'
FROM OLAGNO IS TO TREATMENT

While therapeuti c applicati on of laparoscopy began in the 1930 , the
deve lop~1 e nt of the computer chip televi sion camera was a key piece
of en a b1J~1 g tech.nology for. the u ~ of endoscopy to guide surgery and
therapy 111 additi on to di agnostic uses. Video-endo copy allowed
endoscop ic surgeon s t~ tand upri ght and u e both hands to carry out
the proce~ure. In addition , the entire operating tea m was able to vi ew
th e magnifi ed 1mage on a monitor. In the 1980s, CCD cameras
became small enough that it became po sibl e to integrate them into
too ls. In conjuncti on with these changes was the deve lopment of
spec ialJ.zed tool s for ~~do scop1 c procedures. The e typically had a
form . sm~llar to traditional too l , but with a long straight shaft
all owmg Ill erllon Into the body cavity.
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SEEING "WITHIN"
Whi le endoscopes all owed surgeons to see inside body cavi ti es, their
vision was till limited to the outer surface of organs. Frequent ly
tumour and other abnonna l ti ssues were buried under a layer of
normal tissue. Physicians had to "hunt" around for their targets,
usually in a trial-and-error process that could result in the remova l of
large sections of normal ti ssue. The discovery of X-ray in 1895 by
Wi lliam Rontgen allowed physicians to ee in ide ti ssues for the first
time. X-rays were immediately used for diagnosti c purposes,
including the planning of surgica l interventi ons: 8 day after the
publication of Roentgen' first paper, J. H . Clayton a surgeon in
England used an x-ray print to remove an industrial ew ing needl e
from a woman's hand .6 However, an actual x-ray guided intervention
did not occur until 1963, nearly 70 year later when Charl es Dotter
percutaneousl y dilated a tight tenosis of the superfi cial femora l
artery 7 Today, fluoroscopy-guided interventions seem intuiti ve and a
natural app lication of x-ray images. However, early images could
take up to two hours to produce, and continuous imag ing was not
possible.8
An explosion of new techniques and procedures followed the
key deve lopment of video-endoscop y and inte rve ntional
fluoroscopy as these technologies were applied to a range of different
problems. While these modalities conti nue f01m the main stay of
image-guidance for minimally invasi ve procedures, recent years have
seen the exploration of many other modaliti es for the guidance of
intra-operative procedure . Some example include:
intra-operati ve MRJ for brai n tumour remova l9, epilepsy
surgery 10, ca th eter-b ased aortic va lve pl ace ment 11 ,
catheterizations 12, and stenting of aorti c co-arctation l 3
intra-operati ve CT for brain les ion and sinu surgery 14

estimate the location of interna l structures. A paper published by
Hor ley and lark ( 1908) described a stereotactic device that cou ld
be affi xed to a subj ect's head and aligned using ex terna l landmark
such as the auditory . canals and orbital rim (F igure 3 ).16 Thi s
al1 gnm ent dev1ce prov1ded a coordinate system that co uld be used to
guide the introducti on of electrodes into the kull. Thi s was the first
time an attempt was made to correlate a model of the internal
anatomy with the patient in phys ical pace. Horsley and Clark
as um ~ d that brains pos essed a con tant tru cture and that every
bram IS the sa me as another, and that spec ifi c internal structures
~o uld be targeted by simpl e coordin ates. Although this assumption is
mco rrect, the des ign of the stereotactic frame was a maj or
br.ea kthro~ g h that would later allow pre-operati ve images to be
ali gned w1th the patient for procedure guidance (The in venti on of
stereotacti c frames actuall y preceded the invention of CT and MRJ 1).
~he abi lity to bring models and image
into the patient's
coordmate sy tem was an important step in allowing model s to be
used for pl anning and guidance of procedures. With the in venti on of
CT sca nners in 1973 (Hounsfield , 1919 - 2004), CT stereotactic
surgery beca me possible. The use of pre-operat ive images to guide
mtervent10n s IS a current area of research of research and growth
(F1gure 4). xamples of clinicall y used sy tem in clude the Carto
XP E P Navigat ion System ( me rges CT o r MRI with
electroanatomi ca l information for catheter ab lati ons) and the
Medtronic Stealth Station (merges pre-operat ive CT and MRJ images
w1th tracked surg1ca l too ls and intra-operati ve images) .11.18

ultrasound-guided breast surgery 15
Cost, acquisition speed and diffi cul ty in making the imaging sy tems
OR compatible remain barriers to intra-operative CT and MRI
guidance of surgical procedures. As real-time imaging has grown in
popularity, it ha become increasi ngly important to develop new
surgical tools that do not introduce artifacts into the images. This
requires changes in both the mechanical design and the materia ls
used.
ROADM APS
There were also early attempts at minimall y invasive surgery wi th out
the use of any real-time imagi ng to locate interna l structure . In lieu
of direct visualizati on, a model was used to help the physician

Figure 4. Exa mpl e of multimodality imagi ng showi ng overl ay of
CT and U image of the aortic root.
MOTION AT A DI STANCE

Figure 3. Horsely - Clark stereotactic frame. Image courtesy of the
Sc1ence Museum , London , UK.

With minimall y invas ive access to internal structures through sma ll
ports, too ls became more diffi cult to control and navigate. In
respon e to these chall enges surgical robots were developed . Adapted
from industri al des igns, the first medica l robots were desi gned to
hold a fixture at a specific location in space. 19 The first robot used in
surgery was an indu tri al robot called the PUMA 560 that held a
fixture next to a patient's head to locate a bi opsy tool in neurosurgery
(Figure 5).20 However, shortl y after thi s initial breakthrough, the
company that manufactured the PUMA 560, Unimation Limited, was
sold to Westinghouse Limited, which refused to all ow the robot to be
used for surgica l purposes on the bas is that it was un afe.21 Soon
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Figure 5. Photo of th e PUMA 560. Image co urtesy o f Unm ann ed
So luti o ns Inc.
compani es began deve loping roboti c systems specifica ll y fo r medi ca l
appli cati ons. The first to be tri ed on hum an pati ents was develo ped at
l.BM and ca ll ed the Robodoc. It was used to ho ld a rotatin g c utter
that reamed o ut the prox ima l fe mur to take a prostheti c impl a nt. 22
Today, medi ca l robots are used ro utine ly for many procedures,
inc ludin g coro nary artery bypass g ra ftin g and tra nspubic radi ca l
prostatecto my.
Surg ical robots can provide man y adva ntages, inc ludin g th e
abi lity to move in predefin ed 3D pa ths, th e abi lity to ho ld too ls fo r
long periods of tim e ri g id ly a nd without tremor, th e abi lity to ma ke
precise mi cromoti on a nd th e abili ty for te le-operati on. However,
s urg ical robots can a lso be bu lky, expensive, and diffi c ult to nav iga te.
Today it is sti ll unc lea r w hether surg ica l ro bots prov ide c lini ca l
ad va ntages ove r comp ute r a ided surgery, in w hi ch nav iga ti o n a nd
placement o f surg ica l tools are a ided by images and meas ure me nts
pro vided o n a comp uter, but th e too ls re ma in ma nu a ll y co ntro ll ed by
the surgeo n.

LOOKrNG FORWARD
S ince th e 1980s th ere has bee n an ex plo ive interest in minim a ll y
mvas tve procedures and the tec hno logy be hind it. As ph y ic ia n
become mo re co mforta ble and co nfid e nt w ith th e new tec hn o logy,
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